



Healthcare & Public Health
Sector Coordinating Councils

PUBLIC PRIVATE PARTNERSHIP

1
2

3 MEDICAL DEVICE AND HEALTH IT
4 JOINT SECURITY PLAN

5 January 2019

6
7
8
9
10

11
12
13
14
15
16
17

18
19 **ABOUT THE HEALTHCARE AND PUBLIC HEALTH**
20 **SECTOR COORDINATING COUNCIL**
21 **JOINT CYBERSECURITY WORKING GROUP**

22
23 The Healthcare and Public Health Sector Coordinating Council (HSCC) is a coalition of private-
24 sector, critical healthcare infrastructure entities organized under Presidential Policy Directive 21
25 and the National Infrastructure Protection Plan to partner with government in the identification
26 and mitigation of strategic threats and vulnerabilities facing the sector’s ability to deliver
27 services and assets to the public. The HSCC Joint Cybersecurity Working Group (JCWG) is a
28 standing working group of the HSCC, composed of more than 200 industry and government
29 organizations working together to develop strategies to address emerging and ongoing
30 cybersecurity challenges to the health sector.

31
32 This Medical Device and Health IT Joint Security Plan is the product of a task group established
33 under the auspices of the HSCC JCWG and composed of medical technology, health IT and
34 health delivery organizations, as well as the FDA, to address a major recommendation of the
35 Health Care Industry Cybersecurity Task Force report from June 2017 calling for a cross-sector
36 strategy to strengthen cybersecurity in medical devices.

37
38 To provide feedback on this tool, please send comments to:
39 **JSPFeedback@HealthSectorCouncil.org**

40
41 For more information on the HSCC, see <https://HealthSectorCouncil.org>.

42	Contents	
43	Acknowledgments	4
44	Executive Summary	7
45	Background	7
46	Purpose and Objectives	8
47	JSP Product Security Framework Overview	9
48	How to Use the JSP	10
49	JSP Product Security Framework Implementation	11
50	Evaluating JSP Progress and Maturity	22
51	Appendix A: Acronyms	28
52	Appendix B: Terminology	29
53	Appendix C: Roles and Responsibilities	33
54	Appendix D: Drafting of the Joint Security Plan	35
55	Appendix E: Example Design Input Requirements for Security	39
56	Appendix F: Example Third-Party Security Agreement	41
57	Appendix G: Example Customer Security Documentation	43
58	Appendix H: Example Organizational Structure	47
59	Appendix I: Example Organizational Training	49
60	Appendix J: Example Security Risk Assessment Methods	51
61	Appendix K: CMMI® for Development	51
62		
63		
64		

65 **I Acknowledgments**

66 The following individuals constitute the membership of the committee established in November
67 2017 who were responsible for development of the Medical Device and Healthcare Information
68 Technology Joint Security Plan.

- 69 • **Task Group Co-Chair**, Kevin McDonald, Director of Clinical Information Security, Mayo
70 Clinic
- 71 • **Task Group Co-Chair**, Rob Suarez, Director of Product Security, Becton, Dickinson &
72 Company
- 73 • **Task Group Co-Chair**, Aftin Ross, Senior Project Manager, Center for Devices and
74 Radiological Health (CDRH) at US Food and Drug Administration
- 75 • Bill Hagestad, Independent Information Security Researcher
- 76 • Colin Morgan, Director, R&D & Product Security, Johnson & Johnson
- 77 • Jim Jacobson, Chief Product and Solution Security Officer, Siemens Healthineers
- 78 • Michael McNeil, Global Product Security & Services Officer, Philips
- 79 • Seth Carmody, Cybersecurity Project Manager, CDRH at US Food and Drug
80 Administration
- 81 • Zach Rothstein, Vice President, Technology and Regulatory Affairs, AdvaMed
- 82 • Ronald Mehring, Chief Information and Security Officer/VP of Technology, Texas Health
83 Resources
- 84 • Hitesh Patadia, Enterprise Architect, Alberta Health Services
- 85 • Christopher Bennett, Senior Information Security Analyst, Medical University of South
86 Carolina
- 87 • Greg Garcia, Executive Director at Healthcare Sector Coordinating Council
- 88 • Suzanne Schwartz, Associate Director for Science and Strategic Partnerships, CDRH at US
89 Food and Drug Administration
- 90 • Caleb Eggink, Security Solution Leader, Cerner
- 91 • Ali Nakoulima, Lead Technology Architect, Cerner
- 92 • Regina Geierhofer, Regulatory Affairs Manager, Cerner
- 93 • John Travis, Vice President Regulatory Research, Cerner

- 94 • Ray Smith, Lead Software Engineer, Cerner
- 95 • Greg Thole, Senior Regulatory Strategist, Cerner
- 96 • Wil Vargas, Standards Director, Association for the Advancement of Medical
97 Instrumentation
- 98 • Jim Hanson, Information Security Officer, Avera Health
- 99 • Ashley Woyak, Business Information Security Officer, Baxter Healthcare Corporation
- 100 • Ken Hoyme, Director of Product Security, Boston Scientific
- 101 • Michael Maksymow, CIO, Beebe Healthcare
- 102 • Michael Seeberger, Systems Engineer, Boston Scientific
- 103 • Mari Rose Savickis, Vice President of Federal Affairs, CHIME
- 104 • Fernando Blanco, CHRISTUS Health, VP & CISO
- 105 • Aaron Wishon, CISO, Cook Children’s Health Care System
- 106 • Clyde Hewitt, Vice President, Security Strategy / NCHICA Board of Directors,
107 CynergisTek/NCHICA
- 108 • David Klonoff, President, Diabetes Technology Society
- 109 • Charles Stride, Senior VP, CIO/CISO, Holy Redeemer Health System,
- 110 • Paul Connelly, VP/CISO, HCA Healthcare
- 111 • Peter Amadio, Professor of Biomedical Engineering, Mayo Clinic (AEHIS)
- 112 • Lisa Griffin Vincent, VP of Clinical Science, Medical Device Innovation Consortium
- 113 • Elliott Warren, Director of Federal Affairs, Medical Device Manufacturers Association
- 114 • Zack Hornberger, Director of Cybersecurity & Informatics, Medical Imaging Technology
115 Association
- 116 • Matt Russo, Sr. Director of Global Security Office, Medtronic
- 117 • Ari Entin, CIO, Natividad Medical Center (AEHIS)
- 118 • Katie Boyer, Manager of Policy and Advocacy, Nemours Children’s Health System
- 119 • Jon Crosson, Manager of Special Interest Group Services, H-ISAC

- 120 • Nathan Gibson, CIO, Quality Insights (AEHIS)
- 121 • Kevin Scott, Senior Corporate Director of Security and End User Services, Shriners
122 Hospitals for Children
- 123 • Ross Carevic, Director of Business Technology, Vizient
- 124 • Christine Sublett, President &Principal Consultant, Sublett Consulting, LLC
- 125 • Alex Reniers, Cyber Analyst, US Department of Homeland Security
126
- 127 The HSCC Joint Cybersecurity Working Group TG-1B drafting committee would also like to
128 thank all of the individuals and organizations within the Healthcare Sector Coordinating Council
129 (HSCC) that reviewed and contributed to the plan.
- 130
- 131

132 **II Executive Summary**

133 Software-based medical technologies have the potential to positively impact patient care.
134 However, as these products become more connected, product cybersecurity becomes
135 increasingly important as there is the potential for patient harm and disruption of care if products
136 or clinical operations become impacted because of a cybersecurity concern. As product
137 cybersecurity is a shared responsibility, a wide range of healthcare stakeholders under the
138 umbrella of the Healthcare and Public Health Sector Coordinating Council (HSCC), have drafted
139 this Joint Security Plan (JSP) to address cybersecurity challenges. These challenges include but
140 are not limited to transparency and disclosure between vendors and end users, security by design
141 and throughout the product lifecycle, and product end of life. Specifically, the JSP is a total
142 product lifecycle reference guide to developing, deploying and supporting cyber secure
143 technology solutions in the healthcare environment. It includes:

- 144 • Cybersecurity practices in design and development of medical technology products
- 145 • Handling product complaints relating to cybersecurity incidents and vulnerabilities
- 146 • Managing security risk throughout the lifecycle of medical technology
- 147 • Assessing the maturity of a product cybersecurity program

148 The JSP is voluntary and seeks to aid organizations (medical device manufacturers, healthcare
149 information technology (IT) vendors, and healthcare providers) in enhancing their product
150 cybersecurity irrespective of organization size or maturity. It is intended to be globally
151 applicable, inspire organizations to raise the bar for product cybersecurity, and is expected to
152 evolve as product cybersecurity evolves. As such, it is anticipated that there will be future
153 iterations of the JSP and feedback on this initial version is welcome.

154 It is important for medical device manufacturers (MDMs) and health IT vendors, collectively
155 referred to as vendors, to consider the JSP's voluntary framework and its associated plans and
156 templates throughout the lifecycle of medical devices and health IT because doing so is expected
157 to result in better security and thus better products for patients. Security can be difficult to
158 integrate into existing processes for a variety of reasons such as organizations not recognizing its
159 importance, not knowing where to start, and insufficient resources. The components in the JSP
160 framework are used to help create security policy and procedures that align and integrate into
161 existing processes. Our primary ask of organizations is to make a commitment to implementing
162 the JSP as it is expected that patient safety will be positively impacted as a result.

163

164 **III Background**

165 In the *Cybersecurity Act of 2015* (the Act), the United States Congress established the Health
166 Care Industry Cybersecurity (HCIC) Task Force to identify the challenges that the healthcare
167 industry faces when securing and protecting itself against cybersecurity threats. Industry
168 participation in the task force brought to light critical gap areas warranting focus; year-long
169 discussion and analysis culminated in the release of a set of recommendations and action items to
170 address six high-level imperatives.

171 In 2017, a group of medical device manufacturers stepped up to address the recommendations
172 and action items set forth under Imperative 2 of the HCIC Task Force Report: “Increase the
173 security and resilience of medical devices and health IT” by engaging healthcare delivery
174 organizations in a collaborative effort that would produce a Joint Security Plan. This effort was
175 further formalized under the auspices of the Healthcare Sector Coordinating Council’s Joint
176 Cybersecurity Working Group public-private partnership, as the JSP was broadly socialized with
177 healthcare providers, trade associations, security professionals, and government organizations
178 during development and prior to its release. The U.S. Food and Drug Administration, in its role
179 as a key public sector partner, also assisted with the development of the JSP. For additional
180 information on how the JSP was drafted, please see Appendix D. Imperative 2 of the HCIC Task
181 Force Report states:

182 ***Imperative 2. Increase the security and resilience of medical devices and health IT.***
183 *The Health Care and Public Health (HPH) Sector is charged with keeping patients safe*
184 *and that includes protecting patients from physical harm, as well as privacy-related*
185 *harms that may stem from an exploited known cybersecurity vulnerability. If exploited, a*
186 *vulnerability may result in medical device malfunction, disruption of health care services*
187 *(including treatment interventions), inappropriate access to patient information, or*
188 *compromised EHR data integrity. Such outcomes could have a profound impact on*
189 *patient care and safety. Some foundational challenges that will need to be addressed in*
190 *order to enhance the cybersecurity of medical devices and EHRs include legacy*
191 *operating systems, secure development lifecycle, strong authentication, strategic and*
192 *architectural approaches to product deployment, management, and maintenance on*
193 *hospital networks.*

194 *The relatively short lifespan for operating systems and other relevant platforms such as*
195 *commercial off the shelf software is inherently misaligned in health care as medical*
196 *devices and EHRs may be utilized for 10, 15, 20, or more years. This misalignment may*
197 *occur for a variety of reasons. Hospitals operate on thin budgets and cannot replace*
198 *capital equipment like MRIs as quickly as new operating systems are released. Product*
199 *vendors have a product development lifecycle that may take several years and they may*
200 *start development using one operating system and by the time the product comes to*
201 *market, newer operating systems may be available. Creative ways of addressing the*
202 *aforementioned challenge areas may be found by engaging key clinical and cybersecurity*
203 *stakeholders, including software vendors.*

204
205 The JSP is expected to evolve over time and the HSCC intends to establish a governance model
206 to ensure the baseline strategy is updated based on execution of existing plans or new needs
207 identified by members of the stakeholder community.
208

209 **IV Purpose and Objectives**

210 The HSCC believes that, because medical technology is integral to patient safety and clinical
211 operations, product cybersecurity in medical technology is a shared responsibility among
212 healthcare stakeholders. Moreover, more secure products result in higher quality products
213 which positively impact public health. The JSP is a consensus-based total product lifecycle
214 reference guide for developing, deploying, and supporting cyber secure technology solutions in

215 the health care environment. It is not a regulatory document nor is it a standard. Rather the JSP
216 may be leveraged across an organization’s product portfolio and is intended to be globally
217 applicable. Furthermore, the recommendations provided in the JSP are intended to help
218 organizations of various size and stages of maturity to enhance their product cybersecurity
219 posture by addressing key cybersecurity challenges.

220 This voluntary plan is intentionally forward leaning and seeks to inspire organizations to raise
221 the bar for product cybersecurity. In particular, integrating cybersecurity into an organization
222 necessitates organizational and process changes that come with considerable time and monetary
223 investments. The JSP provides a framework for making these organizational and process related
224 changes.

225 One of the main themes of the JSP is the idea of continuous improvement. We encourage
226 medical device manufacturers, health IT vendors, and healthcare providers to make a
227 commitment to adopting the JSP to aid in developing, deploying, and supporting cyber secure
228 technology solutions in the health care environment. The adoption of the JSP, with the
229 integration into current practices, is expected to provide a safer and more resilient patient care
230 and result in overall improved product quality.


231

232 **V JSP Product Security Framework Overview**

233 The JSP framework establishes that effective cybersecurity is integrated into an organization’s
234 quality system processes and is incorporated throughout the various stages of the
235 commercialization process (from concept to launch). Figure 1 provides a framework for
236 incorporating the JSP into existing quality system processes and throughout commercialization.
237 The core of this framework aligns to traditional quality system concepts. Design controls, risk
238 management, design requirements, testing and post market management can be aligned with
239 multiple software development methodologies (not shown). Documentation of the product
240 security activities/processes in the JSP framework core is encouraged to demonstrate that the
241 framework has been applied consistently and is rigorously followed. Healthcare providers
242 seeking further guidance on the secure operation of medical devices, and other information
243 technology used to run their healthcare operations, may refer to HSCC “[Health Industry
244 Cybersecurity Practices \(HICP\): Managing Threats and Protecting Patients](#)” publication, which
245 stems from the Cybersecurity Information Sharing Act of 2014 (CISA) 405(d) effort. Additional
246 guidance and detail are provided for each product security activity or process identified in the
247 JSP framework in Section VII of this document. Acronyms and term definitions used throughout
248 the JSP may also be found in Appendix A and Appendix B respectively.

249

250



251
 252 **Figure 1. Product Security Framework.** Top row represents product commercialization
 253 phases. Core represents product security activities and processes. Two bottom rows represent
 254 quality system processes

255

256 VI How to Use the JSP

257 For the successful use of the JSP, an initial step is to be able to define the governance process as
 258 it relates to organizational roles and responsibilities, and the needs for personnel training.

259 Governance which may include strategic decisions, establishing milestones, and tracking of
 260 maturity against the framework is executed by designated leaders in a vendor’s organization.
 261 Framework adoption should be driven by mapping each of the framework cybersecurity
 262 activities and processes into existing processes and minimizing the creation of separate or
 263 redundant processes. Again, the goal of implementing the JSP is to generate higher quality
 264 products that positively impact patient safety.

265 In addition to organizational leadership, various members of the organization have a shared
 266 responsibility for product security and thus benefit from the implementation of the JSP. For
 267 example, a vendor may share its evaluation of maturity against the JSP with customers. The
 268 vendor may also share this information with the HSCC with the intent of informing future
 269 iterations of the JSP. Additional granularity regarding stakeholder roles and responsibilities as
 270 well as potential organizational structures for implementing security are found in Appendix C
 271 and Appendix H respectively.

272 Organizations adopting this framework should consider providing existing personnel with
 273 necessary training to achieve focused incorporation of cybersecurity expertise (see Appendix I

274 for additional granularity regarding on organizational training). Maintaining functional
275 competency can best be achieved by establishing a routine training regimen or periodic re-
276 assessment of need.

277

278 **VII JSP Product Security Framework Implementation**

279 This section expands and articulates on security activities and processes in the JSP framework
280 (see Figure 1) in the context of where they align with traditional quality systems processes, and
281 cross references appendices with applicable examples and templates. The goal in adopting the
282 JSP is to integrate the security activities and processes in the JSP framework into existing
283 processes where applicable. For additional information regarding the authoritative sources that
284 were used to draft the content that follows, please see Appendix D.

285 **A. Risk Management**

286 Product security risk assessment is an integral component of overall product risk management.
287 There are specific considerations necessary for ensuring cybersecurity risks identified during
288 design, development, or post launch complaint handling are properly analyzed, evaluated, and
289 documented. This section describes risk management from product concept through product
290 launch.

291 **i. Risk Register**

292 A risk register, also referred to as a risk log, may be standalone or multiple repositories,
293 which can be used to report on efforts across the framework activities, track remediation,
294 and map new known vulnerabilities or potential risks. For vendors, the risk register will
295 be populated from product portfolio management and information from the cybersecurity
296 management plans as described below. Customers also benefit from maintaining a risk
297 register based on information from customer security documentation (see Section VII,
298 Design Control, subsection vi(b) for a description of customer security documentation)
299 and vulnerability disclosures from vendors.

300 **ii. Cybersecurity Management Plan**

301 Beginning at the concept phase, a plan is created to establish how cybersecurity will be
302 managed throughout the product lifecycle of the vendor's product. This plan is
303 maintained throughout the product lifecycle and includes:

- 304 • Reports for product security risk assessment, penetration testing, static code
305 analysis, and vulnerability scanning
- 306 • Documentation of secure coding standards and system hardening standards
307 applied during development and at installation
- 308 • Plans for incident management, vulnerability management, and patch
309 management
- 310 • Documentation of service, remote support, and decommissioning procedures
311 which may also be reflected in service contracts
- 312 • Customer security documentation that is ready for customer distribution
- 313 • Documentation of exceptions (see Section VII, Compliant Handling and
314 Reporting, subsection v for a description of exceptions)

315 This management plan should be cross-functionally reviewed and approved by business
316 leadership in a vendor’s organization. Components of this plan necessary for operation
317 and management of product security are provided to customers by inclusion in customer
318 security documentation, user manuals, and reflected in contractual agreements between
319 the vendor and customer.

320 **iii. Product Security Risk Assessment**

321 **Product Inventory**


322 Document and maintain a comprehensive list of all software enabled products, product
323 versions, solutions, and services commercially available, in support or in development, in
324 order to track cybersecurity risks.

325 Security risk assessment may be performed as part of or separately from other types of
326 risk assessment, including those described in ISO 14971. The objective of risk
327 assessment for known vulnerabilities or potential cybersecurity risks is to determine the
328 comprehensive impact, for example, to clinical safety, business operations, intellectual
329 property, patient privacy, contractual requirements, regulation, and law. The risk
330 assessment will also enable the risks and vulnerabilities to be prioritized for response.
331 Figure 2 is an example of: the sources from which a known vulnerability may be
332 identified; the analysis categories used to score the vulnerability; and the output of the
333 risk assessment. Risk assessments should reflect the target operational environment and
334 use case of the product.

335 Known common vulnerabilities and exposures (CVEs) identified in design and
336 development or during complaint investigation of a launched product are analyzed and
337 evaluated using a consistent vulnerability scoring methodology. One methodology that
338 may be leveraged is the common vulnerability scoring system (CVSS). If CVSS is used,
339 the latest version available should be used at the time of risk assessment to derive the
340 level of cybersecurity risk and information that may be further used in preliminary hazard
341 analysis (PHA), failure mode and effects analysis (FMEA), or other risk assessment tools
342 not specific to cybersecurity, as indicated in Figure 3. Utilizing the most recent version
343 of CVSS can help in this analysis and avoid challenges with determining exploitability
344 for security risks. For many vulnerabilities, CVSS scoring may already be provided based
345 on original equipment manufacturer (OEM) or industry evaluation, but it is recommended
346 that CVSS is calculated specific to the product’s implementation with consideration for
347 worst case scenarios where implementation is not strictly controlled (See Appendix J for
348 more information on a draft CVSS rubric for the healthcare context which may aid in this
349 assessment).

350

351




352
 353 **Figure 2. Risk Assessment Sources.** Assessing risk from different sources and generating
 354 severity scoring that may be used in safety-related risk assessment.

355
 356 As it relates to Figure 2 above:

- 358 • None to low risk means negligible or no impact to confidentiality, integrity, or
 359 availability of the patient, user, vendor or customer environment (environmental)
 360 which may be considered controlled risk.
- 361 • Medium to high risk means potential known vulnerabilities that may result in
 362 adverse events impacting confidentiality, integrity, or availability to the patient,
 363 user, vendor or customer environment which otherwise may be considered
 364 uncontrolled risk depending on impact to safety and efficacy.
- 365 • Critical risk introduces potential for injury or harm to patients or users of products
 366 including impact to sensitive information and data or critical functions which
 367 otherwise may be considered uncontrolled risk.

368



369
370 **Figure 3. Risk Assessment Mapping.** Illustration of how a safety-related risk management
371 process maps to a security-related issue for medical technology

372 **iv. Additional Risk Management Areas**

373 **Supply Chain**

374 Secure, according to a vendor information security policy, development and
375 manufacturing environments such that additional security risk is addressed prior to
376 deployment of a product to a customer. These measures should include malware
377 protection measures, file system integrity checking, and access control for intellectual
378 property during the supply chain process.

379 **Third-Party Entities**

380 It is important that external entities involved in the product lifecycle of a medical device
381 or healthcare information technology ensure applicable components described in the JSP
382 framework (Figure 1) can be achieved. Furthermore, by undergoing routine assessment
383 against the applicable components of this framework, third-party entities demonstrate
384 their commitment to further bolstering the state of medical device and health IT security.
385 Additional granularity is provided in an example of a third-party security agreement in
386 Appendix F.

387 **B. Design Control**

388 Design controls consist of policies and procedures that ensure that product design inputs are met
389 so that correct requirements can be developed. For cybersecurity, organizations apply applicable
390 standards and testing to software code during product development as well as during each
391 software release. These design control principles also apply to components provided by third-
392 parties that are used in finished products. The section that follows describes components of the

393 JSP security framework relevant to design control from product concept through product
394 qualification.

395 **i. Design Input Requirements for Security**

396 As a subset of design input requirements, establish high-level security requirements based
397 on: authoritative sources for security standards and best practices; a vendor’s own
398 security requirements when they verifiably exceed existing standards; regulatory
399 requirements for security of technology or medical technology specifically, and customer
400 feedback relating to security. These requirements should be assessed for applicability to a
401 product during the design and development processes (Figure 1). Additional specifics
402 regarding some of these requirements are found in Appendix E. It is expected that
403 additional information regarding cybersecurity vulnerabilities may be obtained once the
404 product is launched. As a result, it is important to incorporate known cybersecurity
405 vulnerabilities and relevant compensating controls into the design control process (i.e.
406 into design control policy and procedures).

407 **ii. System Requirements, System Hardening Standards, and Vulnerability**
408 **Scanning**

- 409 • Identify, apply and maintain system hardening standards provided by a third-party
410 component vendor or an authoritative source for securely configuring all products
411 and components used in a vendor product. See Appendix D for examples of
412 authoritative sources for standards and testing.
- 413 • Perform vulnerability scanning periodically throughout product development and
414 conduct automated testing to ensure secure system configuration and patching.

415 **iii. Software Requirements, Secure Coding Standards, and Code Analysis**

- 416 • Apply secure coding standards during the development of software that outline
417 secure coding practices generic to any programming language, and language-
418 specific secure coding standards specific to a programming language.
- 419 • Perform static and dynamic code analysis periodically throughout product
420 development testing and integrate automated solutions into development tools to
421 ensure secure coding standards are followed.

422 **iv. Patch Management Requirements**

423 Routinely identify, apply and maintain system-patching throughout the product
424 development process for products and components, including those provided by third-
425 parties. Consider remediation planning within a reasonable timeframe - including an
426 upgrade of the products and components - if patches are no longer supported by their
427 third-party vendor. The deployment and application of patches will have a defined time
428 of disruption to system operation and minimal impact on availability for patient care. See
429 Section VII, Complaint Handling and Reporting, subsection vi for additional granularity
430 on vulnerability and patch management once the product is launched.

431 **v. Security Testing**

- 432 • Conduct robustness testing during unit and integration testing of proprietary
433 software in development; test interfaces such as user interfaces, network
434 protocols, and file inputs for ability to withstand and handle potentially malicious

435 input, as well as denial of service attacks and events; and apply standard IT
436 practices such as vulnerability scanning.
437 • Conduct penetration testing. It is paramount that an independent entity trained
438 and/or certified in cybersecurity verifies cybersecurity testing performed and
439 security controls implemented during design control, as well as in each software
440 release near or at completion of risk remediation. Additionally, they may apply
441 custom cybersecurity testing methodologies based on threat modeling to ensure
442 comprehensive use case coverage. Based on product complexity, connectivity,
443 and integration with customer environments and reliance on customer security
444 controls, a penetration test is recommended on the product in its deployed
445 configuration prior to customer use. Documentation by the vendor of penetration
446 testing reports is critical to include in product design documentation and the
447 cybersecurity management plan; include unmitigated findings in customer
448 security documentation.

449 **vi. Customer Security Requirements**

450 **a) Service and Support Access**

451 When remotely or locally accessing customer systems, it is critical that a vendor
452 maintain permissible security and privacy controls and adhere to customer
453 information security policies. Support tools and processes should be monitored
454 for vulnerabilities and insecure practices. The vendor is responsible for providing
455 customer security documentation which comprehensively describes the control
456 measures implemented. In particular, vendor service and support personnel in
457 collaboration with customers are responsible for:

- 458 • Obtaining consent from the customer prior to accessing customer
459 environments in addition to uniquely identifying service and support
460 personnel upon authentication and authorization to a system. Also, document
461 processes for how and when local and remote access is performed for service
462 and support.
- 463 • Avoiding inclusion of any credentials in product information documentation
464 such as service manuals, which may allow unauthorized access to the product.
465 Default passwords or credentials may be documented when instructions are
466 provided to make those credentials unique.
- 467 • Ensuring system cybersecurity controls are always returned to intended
468 configuration prior to completing any vendor service and support visit.

469
470 In addition:

- 471 • Credentials and passwords should be unique, changed on a regular basis and
472 immediately removed or changed following any service personnel
473 termination.
- 474 • Remote access should be done using some type of multi-factor authentication.
- 475 • Customer data, including patient data, may never leave the site without
476 written consent and approval from the customer. Data should be de-identified
477 when possible and a clear communication of use of the data must be provided.
- 478 • Any use of removable media should be approved by customers and customer
479 information security policies should be adhered to before utilization.

- 480 • Decommissioning or transfer of products and components from a customer
481 facility, or removal for refurbishment, requires any sensitive information and
482 data to be destroyed or transferred with reasonable and appropriate safeguards
483 with the customer's written authorization.
- 484 ▪ Customers may accept responsibility to destroy sensitive information and
485 data from any product if they wish to do so. Clearly document and follow
486 any federal and local regulatory or legal procedures for transfers of this
487 data.
- 488 ▪ Service may determine approved methods for managing sensitive
489 information and data. In accordance with customer data retention
490 requirements, the destruction of this data must be clearly documented and
491 follow any local regulatory or legal procedures.

492 **b) Customer Security Documentation**

493 For any commercialized product, it is critical that the vendor develop and
494 maintain documentation which describes all pertinent security information related
495 to the product. Furthermore, customer security documentation needs to be
496 updated when significant changes occur in existing or new product versions. This
497 documentation is prepared for external distribution and consumption by
498 customers. Customers, in turn, are responsible for processing vendor-provided
499 customer security documentation to complete questionnaires, agreements, and/or
500 risk assessments during product procurement phases and incorporating results into
501 a risk management platform as well as an asset management platform for ongoing
502 management.

503 Customer security documentation provided by vendors includes:

- 504 • All components provided or required for use, also known as a bill of
505 materials, using the common platform enumeration convention and major
506 version number. This would include components such as software
507 (commercial and open source) and firmware required for device operation
- 508 • Description of secure configuration
- 509 • Data flow diagrams that capture items flowing in and out of the device, open
510 network ports and active services, as well as any requirements for network
511 connectivity
- 512 • Remote access methods and tools, if used
- 513 • Access control design including privileged access controls and vendor
514 maintenance and/or service accounts
- 515 • Comprehensive description of the control measures implemented
- 516 • Patch management plan developed by the vendor that identifies any customer
517 responsibility as part of the plan
- 518 • Required cybersecurity controls including malware protection that supported
519 the vendor risk assessment
- 520 • Logging and audit capabilities to support customer security operations

- 521 • Assumptions and requirements at installation and in use to maintain security
 - 522 • Summary of known security risks and considerations, including unmitigated
 - 523 findings from penetration testing
 - 524 • Contact information for the vendor to report incidents, vulnerabilities, or for
 - 525 general inquiries regarding security
- 526 For context regarding what may be included in customer security documentation
- 527 and what it might look like, see Appendix G.

528 **C. Complaint Handling and Reporting**

529 Gathering feedback on the cybersecurity performance of their products post product launch is

530 important for vendors, and complaints are a mechanism for obtaining this feedback. The section

531 that follows provides insight into the types of information vendors may receive and actions they

532 may take as a result.

533 **i. Customer Complaint Escalation**

534 Customer complaint evaluation or investigation by the vendor includes steps to determine

535 if there is a product-related cybersecurity vulnerability or incident. A cross-functional

536 team may be assembled to ensure a coordinated investigation and appropriate response.

537 Specifically, the investigation includes close coordination with the affected customers

538 and appropriate parties. Ensure effective escalation and triage by having adequate

539 procedures and classification for potential cybersecurity issues for handling by service

540 and support. Customers and vendors should perform timely information sharing during an

541 investigation to support rapid response.

542 If the customer product complaint is associated with protected health information or

543 personally identifiable information, then privacy considerations must be accounted for

544 (e.g. privacy notifications, breach investigation) and other potentially affected customers

545 must be notified. The vendor should provide information needed for proper incident

546 response to enable successful breach determinations.

547 If the complaint is associated with vendor managed or owned assets but not a vendor

548 product, such as a service laptop or removable media, then upon receiving the complaint

549 the vendor will inform its information security organization. Depending on the type of

550 incident, notification of privacy or compliance officers may be needed as well. Additional

551 responses may also be needed that include customer or regulatory notification.

552 Risk assessment and remediation planning is an integral part of the complaint

553 investigation. As a part of this assessment, product cybersecurity risks are documented in

554 service and support complaint handling systems in addition to risk management files.

555 Remediation may include advised compensating controls and fixes as appropriate.

556 **ii. Reporting Considerations**

557 In the interest of strengthening cybersecurity within the medical technology ecosystem, it

558 is essential for vendors to communicate cybersecurity vulnerabilities to appropriate

559 stakeholders. In addition to vendor customers, these stakeholders include Cyber

560 Emergency Response Teams (CERTs) and groups that share medical technology

561 vulnerability and threat information (e.g. information sharing and analysis organizations).


562 Vendors should also be aware of any additional reporting and remediation requirements
 563 imposed by regulators in the jurisdictions in which they operate (e.g. FDA guidance on
 564 Postmarket Management of Cybersecurity in Medical Devices for medical device
 565 manufacturers marketing product in the US), as these vulnerabilities may pose patient
 566 safety concerns.

567 **iii. Security Incident Management, Response and Communication**

568 Provide timely responses and communications to all stakeholders impacted by
 569 vulnerabilities and incidents for commercialized products as described below.

- 570 • Manage internally reported issues within 30 days of initial discovery and the
 571 designated cross-functional team provides an update of the issue status to internal
 572 stakeholders and governance every 60 days thereafter until closure.
- 573 • Produce targeted customer bulletins or notifications and post to a public webpage
 574 or deliver via other available mechanisms to customers within 30 days of initial
 575 discovery for customer and third-party reported issues. Evaluate related customer
 576 security documentation to determine if updates are indicated; if deemed
 577 necessary, proceed to update. Provide status updates to customers and third-
 578 parties reporting vulnerabilities and incidents with a routine cadence established
 579 by the cross-functional team while complaint handling investigation is in
 580 progress. Achieving the aforementioned timing for bulletins or notifications by
 581 the vendor during incidents may be dependent on timely and accurate
 582 communication with customers.
- 583 • Coordinate vulnerability disclosures with a Cyber Emergency Response Team
 584 (CERT) and Information Sharing and Analysis Organization (ISAO) recognized
 585 by the FDA. For an overview of vulnerability disclosure terms, definitions,
 586 concepts, guidelines, and benefits please see the international standard and white
 587 paper referenced under “Security Incident Response and Communication” in
 588 Appendix D. Though out of scope for this document, other reporting such as that
 589 required by federal (e.g. the Health Insurance Portability and Accountability Act
 590 (HIPAA)) and state laws, regulatory compliance etc. may be needed. Figure 4
 591 below is an example of a coordinated vulnerability disclosure process.

592



593
 594 **Figure 4. Example coordinated vulnerability disclosure process.** Organizations obtain
 595 vulnerability information by monitoring various sources. Subsequently a potential vulnerability
 596 is identified, assessed, verified, remediated, and communicated as appropriate.

597 **iv. Remediation Planning**

598 Throughout design and development, a product security risk assessment is necessary to
599 determine the level of risk and subsequent actions for security requirements including
600 remediation planning. Below is an example of how low, medium and high risks can be
601 managed.

- 602 • Low risk can be addressed or accepted as is and documented as an exception (see
603 following section to learn more about exceptions)
- 604 • Medium to high and critical risk can be addressed as requirements for design
605 input and mitigated accordingly
- 606 • Routine vulnerability and patch management may be addressed continuously

607 For commercialized products, security risk assessment and remediation planning is
608 performed as part of a post market management (post-launch) process.

- 609 • Low risks may be addressed separately in a reasonable amount of time, but at
610 minimum during the next product or software update
- 611 • Recommendations for medium to high and critical risks, which may align with
612 uncontrolled risks per FDA’s guidance Postmarket Management of Cybersecurity
613 in Medical Devices, include communicating with the customer and user
614 community about the vulnerability, identifying the devices which could
615 potentially be impacted and providing interim control measures to mitigate risk as
616 well as a remediation plan within 30 days of learning of the vulnerability. Patches
617 must be available with at least one of the deployment methods promptly and
618 within a maximum of 60 days after learning of the vulnerability. As soon as
619 possible but no later than 60 days after learning of the vulnerability, the
620 manufacturer fixes the vulnerability, validates the change, and distributes the
621 deployable fix to its customers and user community such that the residual risk is
622 brought down to an acceptable level.
- 623 • Risks which have resulted in an incident where unauthorized disclosure of PHI or
624 PII will require data breach investigation and potential notification to customers
625 in accordance with local laws and regulation. Other sensitive information and
626 data such as intellectual property will require data breach investigation and
627 potential notification to stakeholders.

628 Corrective and preventive action plans (CAPA) are established in compliance
629 with vendor CAPA policy/procedure in order to evaluate the need to correct
630 existing or potential quality issues that impact the security of products and to
631 develop actions to prevent their occurrence or recurrence.

632 **v. Exceptions**

633 An exception is an instance when a cybersecurity risk is identified (both pre- and post-
634 launch of the product) and the vendor determines that no action is needed. As is
635 appropriate in all cases, it is important for the manufacturer to document the risk in the
636 product’s design history file and/or risk management files. For risks documented as
637 exceptions that require compensating controls to reduce the risk to none-to-low risk, a
638 description of the risk and the compensating controls, including associated procedures,
639 should be provided in customer security documentation for the product.

640 **vi. Vulnerability Management and Patch Management**

641 Prior to commercialization, a vendor establishes a cybersecurity management plan to
642 identify, evaluate, and respond to any cybersecurity incident or vulnerability including
643 known and zero-day vulnerabilities. The plan would not be complete without addressing
644 routine patching throughout the product lifecycle. Standardizing a pre-determined
645 frequency for patches and updates is recommended, with a quarterly frequency at
646 minimum. Publishing and coordinating patches in a timely manner so as to mitigate
647 medium to high risk vulnerabilities is of prime importance to any vulnerability and patch
648 management program. Critical elements of a vulnerability and patch management plan
649 include the ability to:

- 650
- 651 • Continuously monitor, track, and plan for cybersecurity incidents, vulnerabilities,
652 upstream patches, and end of support dates from predefined sources based on
653 inventory of firmware, software, communication modules, etc. Products and
654 components (including those contracted components provided by third-party
655 entities) may also be a source of vulnerabilities and should similarly be subject to
656 monitoring
- 657 • Determine the level of risk and subsequent actions necessary to mitigate
658 cybersecurity risks by using product risk assessment, remediation planning and
659 product security risk assessment. In particular, document cybersecurity risks in
660 defect, bug, or issue tracking systems or product backlog, in addition to design
661 history files and/or risk management files
- 662 • Validate the remediation and successful patching of vulnerabilities, including
663 impact to performance and clinical use
- 664 • Perform proper version controlling to ensure patches can be identified once
665 deployed on products
- 666 • Identify capabilities necessary for customers and vendors to determine if a
667 security incident has occurred from any exploited vulnerability
- 668 • Deploy remediation, including routine and emergency software patches, by
669 implementing at least one of the following secured methods that are then
670 documented by both vendor and customer:
 - 671 ▪ Remote Update: Patches applied via secure authorized remote service and
672 support platforms provided by the vendor
 - 673 ▪ Customer Administered: Validated patches will be made available for
674 customer retrieval and installation from a designated source including
675 direct download from the third-party that provides the product or
676 component
 - 677 ▪ Service Visit: Local service administered cybersecurity patches. Note that
678 this method is less optimal due to the time required to deploy local service
679 personnel to customer facilities. However, it has utility in cases where
680 faulty patching has foreseeable and serious safety risk and local service
681 personnel may be required for resolution
 - 682 ▪ Ad-hoc Patching: Customers may accept engineering and technical risk
683 for all other deployment mechanisms and/or application of cybersecurity
684 patches not validated by the vendor. Note that this method is not advised
685 due to the lack of validation by the vendor and potential impact to system
686 performance or patient safety

- 687
- 688
- 689
- 690
- 691
- 692
- 693
- 694
- 695
- 696
- 697
- 698
- Make customers aware of the availability of cybersecurity patches and upgrades for products through a public webpage and/or direct customer notification (e.g., email followed by letter).
 - For vendor-managed remote updates and service visits, routine reporting to customers of failures to patch products in the field is necessary, including products and components provided by third-party entities that are no longer supported by their vendor
 - It is essential that customers establish processes and/or technical means for routinely monitoring the designated communication channels predefined by the vendor for new information or changes regarding patches

vii. End of Life/ End of Support and Decommissioning

699 The cybersecurity management plan incorporates consideration for appropriate actions
700 for the vendor and its customers when security for the product can no longer be supported
701 or when the vendor discontinues support and maintenance of the product.

- 702
- 703
- 704
- 705
- 706
- 707
- 708
- 709
- 710
- 711
- 712
- 713
- 714
- 715
- 716
- 717
- 718
- 719
- 720
- 721
- 722
- 723
- Consideration for end of support includes when third-party products and components are no longer supported by their manufacturer or developer and when known common vulnerabilities and exposures are identified but not remediated by the third-party component manufacturer or developer. Provide anticipated end of life and end of support dates to customers as part of customer security documentation.
 - For commercialized products that will receive an end of life or end of support date for the first time, a reasonable amount of advanced notification is recommended so that customers can take any necessary action including removal of network connectivity, transition to a supported product, and implementation of compensating controls provided by the vendor as part of end of life and end of support. At a minimum, 3 years is considered a reasonable amount of time between communicating and making effective end of life or end of support.
 - Customers should be aware of the end of life and end of support dates for systems in their inventory and make risk-based decisions on their replacement or continued use. If intending to replace, organizations can develop replacement/upgrade plans for each system. If the decision is continued use beyond the end of life and end of support dates, the customer is advised to perform a risk assessment to determine risk reduction strategies it can perform independently, which may include network segmentation, isolation, system hardening, or other defense-in-depth strategies.

724 VIII Evaluating JSP Progress and Maturity

725 A. Evaluating Progress

726 An organization involved in the design, development, production, deployment, service, and
727 support of medical device and healthcare information technology may establish means for
728 achieving each of the applicable plan components with target dates and periodically assessing
729 progress and maturity against the JSP. The table below is an example of a JSP maturity
730 assessment. Once the framework is understood, it is recommended that an initial assessment is

731 completed and the follow-ups scheduled and executed. Note that other maturity assessments may
 732 be of value and additional information on the CMMI maturity assessment is found in Appendix
 733 K.

734

Plan Component	Description	Current Maturity	Target Maturity	Milestones
----------------	-------------	------------------	-----------------	------------

Organization

Structure	Does the organization have a Chief Product Security Officer? Does the organization have a product security function? Are the product security functions roles & responsibilities clearly defined? Is the product security function staffed appropriately?	[1-5]	[1-5]	[YYYY/MM]
------------------	--	-------	-------	-----------

Governance	Are there existing policies and/or procedures that cover product security? Has organizational leadership approved of the product security policy and procedures? Is the organization audited against product security policies/procedures? How frequently? Are product security metrics briefed to leadership such as Chief Quality Officer, Chief Medical Safety Officer, R&D leadership, etc.? If so, how frequently?			
-------------------	--	--	--	--

735

Risk Management

Risk Register	Has an inventory of products been created for	[1-5]	[1-5]	[YYYY/MM]
----------------------	---	-------	-------	-----------

Risk Assessment	<p>commercialized products and products in development?</p> <p>Are security risks tracked in R&D defect tracking systems, design history or risk management files?</p> <p>Are security risks tracked in service complaint handling systems or risk management files?</p>			
	<p>Is there an established method used for security risk assessment?</p> <p>Have policies and procedures been updated to incorporate security risk assessment and triage to other types of risk assessment?</p>			
Supply Chain	<p>Are development and manufacturing environments assessed and managed for adherence to information security policy?</p>	[1-5]	[1-5]	[YYYY/MM]
Third-Party Entities	<p>Have third-parties been assessed against the components of this framework?</p> <p>Are third-parties routinely assessed for security?</p> <p>Does the organization have security requirements in the contract language for suppliers and third-parties?</p>			
Exceptions	<p>Are exceptions to framework components documented in design history and/or risk management files?</p> <p>Are compensating controls associated with exceptions provided in customer security documentation?</p>			

Design Control				
Design Input Security Requirements	Are cybersecurity requirements incorporated in design input for products in development?	[1-5]	[1-5]	[YYYY/MM]
Standards and Testing	<p>Are system hardening standards, system patching, and vulnerability scanning incorporated in product development practices?</p> <p>Are secure coding standards and code analysis incorporated in product development practices?</p> <p>Is security testing such as penetration testing performed by trained cybersecurity professionals during design control?</p> <p>Is robustness testing performed during product development?</p>			
Vulnerability Management & Patch Management	<p>Have processes been instituted to monitor, identify, assess, remediate, and validate security patches for product software and third-party components?</p> <p>Are validated patches deployed using an established method?</p> <p>Can reports be generated to show patching failures?</p> <p>Is there a public webpage where customers can go to identify new patches?</p>			
Customer Requirements	Do service and support personnel have procedures for requesting access to customer			

Cybersecurity Management Plan	<p>systems and restoring security measures?</p> <p>Are controls in place for service personnel to uniquely authenticate to customer systems?</p> <p>Is there established policy and procedures around the use of removable media with products and handling of customer data?</p>			
	<p>Are plans in place to maintain security throughout the lifecycle of a product?</p> <p>Do products have anticipated end of life and/or end of support dates established with consideration to supporting third-party products and components?</p>			
Complaint Handling				
Customer Complaint Escalation	<p>Do escalation procedures define cybersecurity signals?</p> <p>Are customer reported cybersecurity issues documented in complaint handling systems?</p> <p>Are processes in place to ensure review of reported complaints related to cybersecurity?</p>	[1-5]	[1-5]	[YYYY/MM]
	<p>Have processes been established to notify a CERT, ISAO, and/or regulator as appropriate of reported cybersecurity issues?</p>			
	<p>Are internal teams engaged within 30 days of a reported security incident and updated every 60 days thereafter?</p>			

Remediation Planning	Are the incident response processes regularly practiced?			
	Is there a public webpage where bulletins or advisories relating to vulnerabilities or incidents can be posted?			
	Are there clearly defined criteria for remediation of security risk for products in development?			
	Are there clearly defined criteria for remediation of security risk for commercialized product?			
	Are medium to critical vulnerabilities communicated to customers within 30 days?			
	Are medium to critical vulnerabilities remediated within 60 days?			

736 **B. Maturity Levels**

737 The following levels are used to describe the state of maturity for individual components of the
738 Joint Security Plan. In order to move to a higher maturity level, all the elements of previous
739 levels should be satisfied.

740 **Level 1: Initial**

741 One or multiple framework components have been presented to internal stakeholders
742 and plans have been drafted, but there is no proven or formalized process nor people
743 responsible.

744 **Level 2: Managed**

745 Framework components have been planned and execution is underway. The
746 established plans ensure framework components are performed, measured, and
747 controlled with routine visibility provided to management.

748 **Level 3: Defined**

749 All of the framework components have been achieved. Formal policies and
750 procedures have been established as well as incorporated in quality management
751 systems. Internal stakeholders have been provided clear description of activities and
752 are provided training. Deliverables for the framework component are well
753 documented and routinely reviewed among internal stakeholders.

754 **Level 4: Quantitatively Managed**

755 All aspects of a framework component are achieved and various performance metrics
756 are collected to determine areas of improvement. The following are performance
757 metrics that may be considered:

- 758 • Number of reported security complaints
 - 759 ▪ Average response time to customers
 - 760 ▪ Average time to closure for security complaints
 - 761 ▪ Average time to customer communication
- 762 • Number of cybersecurity defects out of design control
 - 763 ▪ Average time to remediation
- 764 • Percentage of patches successfully applied remotely to deployed product
- 765 • Percentage of patches successfully applied by customers to deployed product
- 766 • Percentage of patches successfully applied by service to deployed product
- 767

768 **Level 5: Optimizing**

769 Metrics collected on a framework component are routinely reviewed and process
770 improvement plans are established. Quantitative process improvement objectives are
771 established and continuously revised to reflect changes to industry standards and the
772 JSP. Review of quantitative analysis produces predictable results. Process variation
773 across multiple products is understood and when variation produces under-
774 performance it is addressed through the creation of process improvement plans with
775 cross-functional ownership. The process of continuous improvement is intrinsic to all
776 those involved in the design, development, production, deployment, service, and
777 support of medical device and healthcare information technology.
778

779 **Appendix A: Acronyms**

780 This appendix section provides an overview of the acronyms used in this document.

781	C-I-A	Confidentiality Integrity Availability
782	CISO	Chief Information Security Officer
783	DHS	U.S. Department of Homeland Security
784	EHR	Electronic Health Record
785	EU	European Union
786	FDA	U.S. Food and Drug Administration
787	GDPR	General Data Protection Regulation
788	HDO	Healthcare Delivery Organization
789	HCIC Task Force	Health Care Industry Cybersecurity Task Force
790	HHS	U.S. Department of Health and Human Services
791	HIMSS	Healthcare Information and Management Systems Society

792	HIPAA	Health Insurance Portability and Accountability Act
793	HPH	Healthcare and Public Health
794	IT	Information Technology
795	ISAO	Information Sharing and Analysis Organization
796	ISAC	Information Sharing and Analysis Center
797	MDM	Medical Device Manufacturer
798	NIST SP	National Institute of Standards and Technology Special Publication
799	NIS	Network and Information Systems Directive (EU) 2016/1148)
800	H-ISAC	Health Information Sharing and Analysis Center
801	NCCoE	National Cybersecurity Center of Excellence
802	NSA	National Security Agency
803	PHI	Protected Health Information
804	PII	Personally Identifiable Information
805	R&D	Research and Development
806	SDL	Security Development Lifecycle
807	SDLC	Software Development Life Cycle
808	U.S.	United States
809		

810 **Appendix B: Terminology**

811 Various cybersecurity and healthcare centric terms are used throughout this document. This
812 appendix section provides an overview of what is meant by some of these key terms. Note that
813 some of these terminologies and definitions were derived from authoritative sources listed in
814 Appendix D which describes the drafting of the Joint Security Plan.

815 **Code Analysis:** Source code analysis is the automated testing of a program’s source code with
816 the purpose of finding faults and fixing them before the software is sold or distributed.

817 **Common Platform Enumeration (CPE):** An industry standard structured naming scheme for
818 information technology systems, software, and packages.

819 **Common Vulnerability Exposure (CVE):** CVE is a list of information security vulnerabilities
820 and exposures that aims to provide common names for publicly known problems

821 **Common Vulnerability Scoring System (CVSS):** A security industry standard for prioritizing
822 the severity of security issues.

823 **Compensating Controls:** Alternative security controls employed by organizations in lieu of
824 specific controls. These are controls that provide equivalent or comparable protection for
825 organizational information systems and the information processed, stored, or transmitted by
826 those systems.

827 **Complaint Handling:** Process for receiving, reviewing, and evaluating complaints.

828 **Coordinated Vulnerability Disclosure:** The process of gathering information from
829 vulnerability finders, coordinating the sharing of that information between relevant stakeholders,
830 and disclosing the existence of software vulnerabilities and their mitigations to various
831 stakeholders, including the public

832 **Controlled Risk:** Controlled risk is present when there is sufficiently low (acceptable) residual
833 risk of patient harm due to a device’s particular cybersecurity vulnerability.

834 **Critical Functions:** Any product functionality which impacts the clinical safety or significantly
835 disrupts the business operations of Customers.

836 **Customers:** Includes healthcare providers and patients.

837 **Customer Complaint:** Complaint means any written, electronic, or oral communication that
838 alleges deficiencies related to the identity, quality, durability, reliability, safety, effectiveness, or
839 performance of a medical device or health information technology after it is released for
840 distribution.

841 **Customer Incident:** An occurrence from a customer’s use of software, products or services that
842 actually or potentially results in adverse consequences to (adverse effects on) (poses a threat to)
843 an information system or the information that the system processes, stores, or transmits and that
844 may require a response action to mitigate the consequences.

845 **Customer Security Documentation:** Security information provided to customers to enable
846 more robust risk assessments, identify configurable security controls, and allow them to better
847 protect their systems.

848 **Customer Security Requirements:** A user, or potential user, of a system’s functional and non-
849 functional requirements that achieve the security attributes of a system.

850 **Decommissioning:** The first physical process in the disposition process and includes proper
851 identification, authorization for disposition, and sanitization of the equipment, as well as removal
852 of Patient Health Information (PHI) or software, or both.

853 **Design:** A process of defining the architecture, modules, interfaces and data for a system to
854 satisfy specified requirements.

855 **Design control:** The application of a formal methodology used to conduct product development
856 activities.

857 **Design Input Requirements:** The physical and performance characteristics of a product that are
858 used as the basis for product design.

859 **Dynamic Code Analysis:** The testing and evaluation of a program by executing data in real-
860 time. The objective is to find errors in a program while it is running, rather than by repeatedly
861 examining the code offline.

862 **End of Life:** Indicates that the product is in the end of its useful life, as defined by the vendor,
863 and a vendor stops marketing, selling, or making major design changes in sustaining the product.

864 **End of Support:** A point beyond which the product manufacturer ceases to provide support,
865 which may include cybersecurity support, for a product or service.

866 **Exceptions:** An instance when a cybersecurity risk is identified (both pre- and post-launch of the
867 product) and the vendor determines that no action is needed.

868 **Failure Mode and Effects Analysis (FMEA):** A step-by-step approach for identifying all
869 possible failures in a design, a manufacturing or assembly process, or a product or service.

870 **Fuzz Testing:** A software testing technique, often automated or semi-automated, that involves
871 providing invalid, unexpected, or random data to the inputs of a computer program. The program
872 is then monitored for exceptions such as crashes, failing built-in code assertions or for finding
873 potential memory leaks. Fuzzing is commonly used to test for security problems in software or
874 computer systems and is a type of robustness testing.

875 **Harm:** Injury or damage to the health of people, or damage to property or the environment.

876 **Hazard:** Potential source of harm.

877 **Hazard Analysis:** The first step in a process used to assess risk and used to identify different
878 types of hazard.

879 **Incident Response:** Actions taken to mitigate or resolve a security incident.

880 **Internal/External Security Audit:** Review and examination of data processing system records
881 and activities to test for adequacy of system controls, to ensure compliance with established
882 security policy and operational procedures, to detect breaches in security, and to recommend any
883 indicated changes in control, security policy, and procedures.

884 **Malware:** A program that is inserted into a system, usually covertly, with the intent of
885 compromising the confidentiality, integrity, or availability of the data, applications, or operating
886 system. This includes both known and unknown (Zero Day) viruses, spyware, ransomware, and
887 other forms of malicious code that exploit vulnerable systems.

888 **Patch Management:** The systematic monitoring, identification, assessment, remediation,
889 deployment, and verification of operating system and application software code updates. These
890 updates are known as patches, hot fixes, and service packs to operating systems, third-party
891 products and components, and in-house developed software.

892 **Patient Harm:** Physical injury or damage to the health of patients, including death.
893 Cybersecurity exploits (e.g. loss of authenticity, availability, integrity, or confidentiality) of a
894 device may pose a risk to health and may result in patient harm.

895 **Patient Safety:** The prevention of harm to patients including that which may occur from
896 cybersecurity related events.

897 **Penetration Testing:** A test methodology in which assessors, using all available documentation
898 such as system design and working under specific constraints, attempt to circumvent the security
899 features of an information system.

900 **Preliminary Hazard Analysis (PHA):** A technique used in the early stages of system design. It
901 focuses on identifying apparent hazards, assessing the severity of potential accidents that could
902 occur involving the hazards, and identifying safeguards for reducing the risks associated with the
903 hazards.

904 **Product Lifecycle:** Managing the entire lifecycle of a product from inception, through
905 engineering design and manufacture, to service and disposal of manufactured products.

906 **Product Security Risk Assessment:** Overall process of risk analysis and a risk evaluation for
907 security issues found in products using impact to confidentiality, integrity, and availability to
908 patients, customers, and vendor to determine the acceptability of the risk.

909 **Remediation:** Countermeasures to reduce a cyber asset's susceptibility to cyber-attack over a
910 range of attack tactics, techniques, and procedures.

911 **Remediation Planning:** Planning of processes and actions by which organizations identify and
912 resolve threats to their system.

913 **Remote Access:** Access to a product or an organization's non-public information system by an
914 authorized user such as Service and Support communicating through an external network.

915 **Remote Support:** Support activities conducted by individuals communicating through an
916 external network (e.g., the Internet).

917 **Removable Media:** Portable electronic storage media such as magnetic, optical, and solid-state
918 devices, which can be inserted into and removed from a computing device and used to store text,
919 video, audio, and image information. Such devices have no independent processing capabilities.
920 Examples include hard disks, floppy disks, zip drives, compact disks, thumb drives, pen drives,
921 and similar USB storage devices.

922 **Risk Management:** Risk management is an integral part of the medical device product
923 development lifecycle. It is a systematic application of management policies, procedures and
924 practices to the tasks of analyzing, evaluating, controlling, and monitoring risk.

925 **Robustness Testing:** A testing methodology to detect the vulnerabilities of a component under
926 unexpected inputs or in a stressful environment.

927 **Secure Coding Standards:** Guidelines for writing software code that mitigates common
928 security flaws specific to a programming language or in general to all software.

929 **Security Incident:** An event that may indicate that a device's data and security may have been
930 compromised. This includes, but is not limited to:

931 • Attempts to gain unauthorized access to a system or its data
932 • Unwanted disruption or denial of service
933 • Unauthorized use of a system for the processing or storage of data
934 • Changes to system hardware, firmware or software characteristics without owner's
935 knowledge, instruction or consent

936 **Security Management Plan:** Used to document all framework components carried out through
937 the design process and post commercialization. May also capture technical and process gaps,
938 including exceptions. May be incorporated in a product risk management file or equivalent.

939 **Security Requirements:** A set of design-level requirements that comprise a product or other
940 commercial offerings, ensure security issues are mitigated in both software and system
941 components during design control, and are processed through Risk Management.

942 **Sensitive Information and Data:** Protected health information (PHI), personally identifiable
943 information (PII), proprietary software source code or business logic, configuration parameters,
944 user credentials, cryptographic keys, quality control and calibration results.

945 **Static Code Analysis:** The automated analysis of software code for security flaws and adherence
946 to a secure coding standard.

947 **System Hardening Standards:** A documented process or mechanism for securely configuring
948 or implementing commonly used technologies.

949 **Third-Party Entities:** External individuals and organizations such as vendor and suppliers
950 involved with products or acquisition, that collaborate at any point in the product lifecycle,
951 including acquisition, development and servicing.

952 **Threat Modeling:** Structured activity for identifying and managing threats.

953 **Threat Monitoring:** Solutions or processes dedicated to continuously monitoring systems,
954 networks and endpoints for signs of a security threat such as intrusions or data exfiltration.

955 **Threat Source:** The intent and method targeted at the intentional exploitation of a vulnerability
956 or a situation and method that may accidentally trigger a vulnerability.

957 **Uncontrolled Risk:** Uncontrolled risk is present when there is unacceptable residual risk of
958 patient harm due to inadequate compensating controls and risk mitigations.

959 **Validation:** Establishing by objective evidence that specified requirements conform with user
960 needs and intended use(s).

961 **Vendors:** Includes medical device manufacturers and health IT vendors.

962 **Verification:** Confirmation by objective evidence that the results of the design effort meet the
963 design input.

964 **Vulnerability:** A weakness in an information system, system security procedures, internal
965 controls, or implementation that could be exploited or triggered by a threat source.

966 **Vulnerability Disclosure:** Policy practiced by organizations as well as individuals regarding the
967 disclosure or publishing of information about security vulnerabilities and exploits pertaining to a
968 computer system, network or software.

969 **Vulnerability Scanning:** The automated analysis and detection of vulnerabilities such as
970 missing patches and misconfiguration in operating systems and other third-party software.

971

972 **Appendix C: Roles and Responsibilities**

973 Numerous stakeholders may leverage and benefit from the security activities and processes
974 described in this document. To provide additional context, the roles and responsibilities of these
975 stakeholders are described in this appendix section.

976 **For customer stakeholders**

977 1. **Patients:** Review security documentation provided by vendors and healthcare providers
978 for consumer products and in-home environments such that cybersecurity risks are
979 understood and managed.

980 2. **Healthcare Providers:** Assess the risk of new information systems entering their
981 facilities; manage risks over the lifecycle of these information systems, including
982 monitoring of vulnerability disclosures, maintaining patches, securing network
983 environments and enterprise systems; and provide training for their associates on their
984 roles for managing cybersecurity. Also referred to as healthcare delivery organizations
985 (HDOs).

986 **For vendor stakeholders**

- 987 1. **Medical Device Manufacturers:** Responsible for implementing security throughout the
988 design, development, and complaint handling for medical devices. In addition,
989 responsible for providing timely communication to customers in the form of product
990 security documentation, vulnerability disclosures, and the availability of security patches.
- 991 2. **Health IT Vendors:** Responsible for implementing security throughout the design,
992 development, and complaint handling for healthcare information technology. In addition,
993 responsible for providing timely communication to customers in the form of product
994 security documentation, vulnerability disclosures, and the availability of security patches.
- 995 3. **Product Security:** Creation and maintenance of policies, procedures, tooling, guidance,
996 training and awareness for product security across business units and functions. Product
997 security will support product security risk assessments, automated security testing,
998 penetration testing, remediation planning services for R&D and complaint handling.
- 999 4. **Quality:** Ensures the framework is aligned and consistent with other corporate policies,
1000 as well as global regulations and standards for product development, risk management,
1001 manufacturing, and support. Quality, jointly with product security, will ensure adherence
1002 to the framework as with any other quality policy such as risk management and reporting
1003 requirements.
- 1004 5. **Research and Development (R&D):** Responsible for incorporating security in
1005 budgeting and resource planning; provides technical information for product security risk
1006 assessment; establishes design requirements in the development process and throughout
1007 the product lifecycle including post-commercialization maintainability. R&D will
1008 maintain record of security defects in accordance with the business unit quality
1009 management systems including design control and risk management procedures.
- 1010 6. **Product & Portfolio Management (PM, PPM):** Responsible for ensuring product
1011 security is incorporated in budget, resource, project, and roadmap planning activities
1012 throughout the product lifecycle.
- 1013 7. **Complaint Handling Unit:** Responsible for identifying complaints that have a product
1014 security impact and proper escalation of complaints.
- 1015 8. **Service and Support:** Ensure proper response to security incidents and events with
1016 products at customer sites, including proper documentation records as per business unit
1017 complaint handling procedures. Secure service assets, maintain validated security updates
1018 and ensure secure implementation, periodic reporting of security incident and events and
1019 security update tracking.
- 1020 9. **Business Unit and Regional Leadership:** Responsible for communication, compliance
1021 and adherence of the framework at the regional and local business levels. This may
1022 include the creation of local policies that align with and supplement where needed due to
1023 regional laws and regulation the over-arching framework.
- 1024 10. **Legal:** Provides business units with guidance on incident response, adherence to local
1025 security and privacy laws to ensure legal content meets policies.
- 1026 11. **Privacy:** Ensures the appropriate protection of data, such as information from or about
1027 our employees, our customers, and users of our products worldwide.
- 1028 12. **Regulatory:** Provides business units and product security with guidance on local
1029 security and privacy regulation, including any upcoming changes to those regulations.

- 1030 13. **Information Security:** Ensures vendor managed assets, including but not limited to
 1031 laptops, desktop computers, servers, removable media, and networks that interact with
 1032 products align and adhere to the vendor information security policy.
 1033 14. **Third-Party Entities:** Adhere to requirements in the framework and vendor information
 1034 security procedure. Document any exceptions in design history and/or risk management
 1035 files.

1036

1037 **Appendix D: Drafting of the Joint Security Plan**

1038 The intent and purpose of this appendix section is to outline and explain the drafting process and
 1039 authoritative sources used to address traceability to US and International standards for the
 1040 Medical Device and Health IT Joint Security Plan.

1041 In November of 2017, with facilitation by the Healthcare Sector Coordinating Council (HSCC),
 1042 an initial draft of the Joint Security Plan was developed by a group of medical device
 1043 manufacturers, health IT vendors, and FDA representatives.

1044 In February of 2018, through the Health Information Sharing and Analysis Center (H-ISAC) and
 1045 HSCC, a group of healthcare providers was invited to participate in the drafting process of the
 1046 Joint Security Plan.

1047 Following the review by medical device manufacturers, health IT vendors, and healthcare
 1048 providers, the HSCC invited government and policymakers to provide feedback and promote use
 1049 of the Joint Security Plan among all stakeholders referenced in the document.

1050 There are many different authoritative sources which were used to develop and/or can be used to
 1051 achieve aspects of the Joint Security Plan. The following is a list of those sources and the
 1052 associated section in the Joint Security Plan:

1053

1054

JSP Framework Overview	
Health Industry Cybersecurity Practices (HICP): Managing Threats and Protecting Patients publication	https://www.phe.gov/Preparedness/planning/405d/Documents/HICP-Main-508.pdf
Risk Management	
AAMI TIR 57	http://www.aami.org/productspublications/ProductDetail.aspx?ItemNumber=3729
IEC 80001-1	https://www.iso.org/standard/44863.html
NIST CSF	https://www.nist.gov/cyberframework
An Introduction to Computer Security: the NIST Handbook	https://nvlpubs.nist.gov/nistpubs/legacy/sp/nistspecialpublication800-12.pdf

ISACA Risk IT Framework for Management of IT Related Business Risks	http://www.isaca.org/Knowledge-Center/Risk-IT-IT-Risk-Management/Pages/default.aspx
ISO 14971:2007 Medical devices -- Application of risk management to medical devices	https://www.iso.org/standard/38193.html
Risk Assessment	
Common Vulnerability Scoring System	https://www.first.org/cvss/user-guide
NIST Special Publication 800-30 Revision 1.0 2012 Guide For Conducting Risk Assessments	https://nvlpubs.nist.gov/nistpubs/Legacy/SP/nistspecialpublication800-30r1.pdf
Design Control	
Content of Premarket Submissions for. Management of Cybersecurity in. Medical Devices	https://www.fda.gov/downloads/medicaldevices/deviceeregulationandguidance/guidancedocuments/ucm356190.pdf
UL 2900-1 Standard for Software Cybersecurity for Network-Connectable Products, Part 1: General Requirements	https://standardscatalog.ul.com/standards/en/standard/2900-1_1
UL 2900-2-1 Software Cybersecurity for Network-Connectable Products, Part 2-1: Particular Requirements for Network Connectable Components of Healthcare and Wellness Systems	https://standardscatalog.ul.com/standards/en/standard/2900-2-1_1
NIST SP 800-160 Systems Security Engineering. Considerations for a Multidisciplinary Approach in the. Engineering of Trustworthy Secure Systems	http://nvlpubs.nist.gov/nistpubs/SpecialPublications/NIST.SP.800-160.pdf
Catalog of Control Systems Security: Recommendations for Standards Developers	https://ics-cert.us-cert.gov/sites/default/files/documents/CatalogofRecommendationsVer7.pdf
Secure Architecture Design	https://ics-cert.us-cert.gov/Secure-Architecture-Design
NIST Cybersecurity Practice Guide SP 1800-8, Wireless Infusion Pumps	https://nccoe.nist.gov/sites/default/files/library/sp1800/hit-infusion-pump-nist-sp1800-8a-draft.pdf
NIST SPECIAL PUBLICATION 1800-8B Volume B:	https://nccoe.nist.gov/sites/default/files/library/sp1800/hit-infusion-pump-nist-sp1800-8b-draft.pdf

Approach, Architecture, and Security Characteristics	
Secure Software Development Life Cycle Processes	https://www.us-cert.gov/bsi/articles/knowledge/sdlc-process/secure-software-development-life-cycle-processes
OWASP Security By Design Principles	https://www.owasp.org/index.php/Security_by_Design_Principles#Security_principles
Standards and Testing	
DISA Security Technical Implementation Guides	https://iase.disa.mil/stigs/Pages/a-z.aspx
NIST Checklists	https://www.nist.gov/programs-projects/national-checklist-program
NSA Guides	https://www.nsa.gov/ia/mitigation_guidance/security_configuration_guides/
CIS Benchmarks	https://benchmarks.cisecurity.org/downloads/benchmarks/
SEI CERT Coding Standards	https://www.securecoding.cert.org/confluence/display/seccode/SEI+CERT+Coding+Standards
OWASP Secure Coding Practices	https://www.owasp.org/index.php/OWASP_Secure_Coding_Practices_-_Quick_Reference_Guide
MS Secure Coding Guidelines	https://msdn.microsoft.com/en-us/library/fkytk30f(v=vs.110).aspx
Improving Industrial Control System Cybersecurity with Defense-in-Depth Strategies	https://ics-cert.us-cert.gov/sites/default/files/FactSheets/ICS-CERT_FactSheet_Defense_in_Depth_Strategies_S508C.pdf
Vulnerability and Patch Management	
ISO/IEC 30111	https://www.iso.org/standard/53231.html
NIST National Vulnerability Database	https://www.nist.gov/programs-projects/national-vulnerability-database-nvd
CVE Details	https://www.cvedetails.com/index.php
Department of Homeland Security ICS-CERT Division	https://ics-cert.us-cert.gov/advisories
Carnegie Mellon University Software Engineering Institute	https://www.kb.cert.org/vuls/
Guide for Cybersecurity Event Recovery	https://nvlpubs.nist.gov/nistpubs/SpecialPublications/NIST.SP.800-184.pdf

SANS Vulnerability Management	https://www.sans.org/reading-room/whitepapers/projectmanagement/building-vulnerability-management-program-project-management-approach-35932
Customer Security Documentation	
HIMMS/NEMA Manufacturers Disclosure Statement for Medical Device Security (MDS2)	http://www.himss.org/resourcelibrary/MDS2
Software Identification Tags (SWID)	https://nvd.nist.gov/products/swid
Common Platform Enumeration (CPE)	https://csrc.nist.gov/projects/security-content-automation-protocol/specifications/cpe/
Reporting Considerations	
Postmarket Management of Cybersecurity in Medical Devices	https://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm482022.pdf
Security Incident Response and Communication	
ISO/IEC 29147	https://www.iso.org/standard/72311.html
Medical Device Cybersecurity Report: Advancing Coordinated Vulnerability Disclosure	http://mdic.org/wp-content/uploads/2018/10/MDIC-CybersecurityReport.pdf
Evaluating Joint Security Plan Progress and Maturity	
Capability Maturity Model Index	http://cmmiinstitute.com/capability-maturity-model-integration
Cyber Threat Source Descriptions	https://ics-cert.us-cert.gov/content/cyber-threat-source-descriptions
Overview of Cyber Vulnerabilities	https://ics-cert.us-cert.gov/content/overview-cyber-vulnerabilities

1055

United States of America	
21 CFR 806	https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=806&showFR=1
HIPAA – HITECH	https://www.hhs.gov/hipaa/for-professionals/special-topics/hitech-act-enforcement-interim-final-rule/index.html
National Infrastructure Protection Plan (NIPP)	https://www.dhs.gov/cisa/national-infrastructure-protection-plan

European Union	
93/42/CE	https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CONSLEG:1993L0042:20071011:en:PDF
EU General Data Protection Regulation (GDPR)	https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32016R0679
Medical Device Regulations (MDR)	https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:L:2017:117:TOC
Network and Information Systems (NIS) Directive	https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=uriserv:OJ.L_.2016.194.01.0001.01.ENG&toc=OJ:L:2016:194:TOC
Canada	
The Personal Information Protection and Electronic Documents Act (PIPEDA)	https://www.priv.gc.ca/en/privacy-topics/privacy-laws-in-canada/the-personal-information-protection-and-electronic-documents-act-pipeda/

1056

1057 **Appendix E: Example Design Input Requirements for** 1058 **Security**

1059 The controls and features included in device design are informed by the device type, design, use
1060 environment, and intended use or functionality. As such, there is no one size fits all set of design
1061 inputs that should be utilized. Design inputs highlighted here in this appendix section are not
1062 intended to be comprehensive; rather, they serve as examples of input requirements that could be
1063 considered within the context of use for a given device. These design input requirements are
1064 categorized by OWASP Security Design Principles.

1065

1066

- **Minimize Attack Surface**

1067

1. The system shall restrict access of removable media to what is necessary for intended use.

1068

2. Execution of software on the system shall be restricted to explicitly authorized or validated software components.

1069

3. The system shall provide capability to anonymize exported data such that an individual or customer is not identifiable.

1070

4. Ports, protocols, services and addresses available on the system and its network connection shall be restricted to the minimum necessary for intended use and configurable locally by authorized user.

1071

5. The system shall be capable of enabling and disabling particular protocol stacks, individual ports and services, and contains manageable host-based firewall.

1072

6. The system shall provide capability to explicitly enable or disable remote access to the system.

1073

1074

1075

1076

1077

1078

1079

- 1080 7. The system shall notify users to change default passwords after initial use.
- 1081 8. The system shall be capable of restricting repeated and failed user access
- 1082 attempts.
- 1083 ● **Establish Secure Defaults**
- 1084 9. The system shall have the ability to require a minimum password length.
- 1085 10. The system shall have the ability to require a minimum password complexity.
- 1086 11. The system shall have the ability to require periodic password renewal.
- 1087 12. The system shall have the ability to restrict password reuse.
- 1088 13. The system shall have the capability to automatically or manually back-up data
- 1089 necessary for intended use locally or to an external location.
- 1090 14. All sensitive information and data shall be encrypted in transit and at rest using an
- 1091 industry-accepted encryption mechanism and practice.
- 1092 15. The system shall prominently notify users when sensitive information and data
- 1093 are displayed on screen or if encryption is disabled in transit.
- 1094 16. The system shall have routine functionality for handling exceptions, errors and
- 1095 aborts that does not expose sensitive information and data.
- 1096 17. The system shall enforce strict order of execution during system start and end.
- 1097 18. All remote or local user activity which interacts with sensitive information and
- 1098 data as well as critical functions on the system shall be recorded in an audit log.
- 1099 19. All audit log entries shall include a start and end date-timestamp, user ID,
- 1100 role/privileges at time of access, success/failure and a description of the action
- 1101 performed.
- 1102 20. The audit log shall locally retain an individual entry for a configurable period of
- 1103 time or allocation of file system space.
- 1104 21. The system shall provide capability for a user to reset their own password or
- 1105 administrative reset, which is logged.
- 1106 22. The system shall provide the ability to create and assign a unique user ID and
- 1107 password to each remote or local user.
- 1108 ● **Principle of Least Privilege**
- 1109 23. Execution of software on the system shall be limited to the minimum privileges
- 1110 necessary.
- 1111 24. The system shall support the creation and assignment of roles that grant the
- 1112 minimum user privileges necessary for intended use of data and functions.
- 1113 ● **Principle of Defense in Depth**
- 1114 25. The system shall support multiple factors for user authentication and capable of
- 1115 centralized authentication.
- 1116 26. The system shall provide capability to prevent the execution of known malicious
- 1117 software.
- 1118 27. The system shall be capable of manually or automatically locking the display and
- 1119 requiring user authentication after a configurable period of user inactivity in order
- 1120 to continue use such that sensitive information and data are not visible.
- 1121 28. The system shall provide capability for a user to reset their own password or
- 1122 administrative reset, which is logged.
- 1123 ● **Fail Securely**
- 1124 29. The system shall be capable of restoring functionality to an operational state.
- 1125

- 1126 ● **Don't Trust Services**
- 1127 30. The integrity and composition of all data as input or output of the system shall be
- 1128 validated such that modification is detected and/or rejected.
- 1129 31. All remote or local access to the system by user or an external system shall be
- 1130 authenticated prior to granting access to data or functions.
- 1131 ● **Separation of Duties**
- 1132 32. The audit log shall be restricted in access to only authorized users.
- 1133 33. The audit log shall be exportable and readable by authorized users and have the
- 1134 capability to integrate with security information and event management for real-
- 1135 time analysis.
- 1136 ● **Avoid Security by Obscurity**
- 1137 34. The security of a system shall not rely upon knowledge of the source code or
- 1138 shared hard coded credentials being kept secret.
- 1139 ● **Keep Security Simple**
- 1140 35. The system shall allow security controls to be configured with no significant
- 1141 downtime and centrally managed by authorized users.
- 1142 ● **Fix Security Issues Correctly**
- 1143 36. The system shall support authorized updates to mechanisms for controlling the
- 1144 execution of authorized or malicious software.
- 1145 37. Components of the system shall support software updating and patches with no
- 1146 significant downtime using standard centralized patch management systems.
- 1147

1148 **Appendix F: Example Third-Party Security Agreement**

1149 It is important for vendors to consider the security of various components in their supply chain at
 1150 the time of procurement. This appendix section specifies security requirements applicable to
 1151 third-party suppliers that provide product development and post-market product management
 1152 services to a given vendor.

1153 The supplier is responsible for understanding the risk of [Company] and [Company's]
 1154 customers' information and products it will access, process, manage, or store in the performance
 1155 of services to [Company], and [Company's] customers. Compliance with the Association for the
 1156 Advancement of Medical Instrumentation's (AAMI) "Technical Information Report (TIR) 57 -
 1157 Principles for medical device security—Risk management" is recommended for meeting these
 1158 objectives.

1159 **1. PRODUCT DEVELOPMENT**

- 1160 1.1 Cybersecurity requirements are evaluated and documented during product design.
- 1161 1.2 Cybersecurity threats and risks are evaluated and documented as part of a risk
- 1162 analysis process during product design.
- 1163 1.3 Cybersecurity testing is completed as a part of verification and validation
- 1164 activities. Testing includes, but is not limited to, the following:
- 1165 a) Vulnerability scanning
- 1166 b) Static/binary code scanning
- 1167 c) Fuzz testing
- 1168 d) Customized test cases to evaluate defined cybersecurity
- 1169 requirements

- 1170 e) Penetration tests
1171 1.4 Cybersecurity penetration test is performed before the product is launched.
1172 1.5 Defects identified during security testing shall be documented and evaluated for
1173 correction based on risk analysis process.
1174 1.6 A software inventory or bill of materials shall be documented identifying all
1175 software of unknown provenance (SOUP) and third-party software components in
1176 a device and any backend support and specialist development systems.
1177 a) A security assessment of third party and SOUP components is
1178 performed to determine version and patches are up to date and existing
1179 vulnerabilities are evaluated for risk and corrective action.
1180 b) At the request of [Company] product owners and stakeholders,
1181 documentation and/or evidence of the above shall be made available.
1182 c) At the request of [Company] product owners and stakeholders,
1183 source code and or binary files shall be made available.
1184 d) Licensing arrangements for third party software, that establishes
1185 permissions for use, longevity and liabilities shall be negotiated with
1186 [Company] prior to incorporating such code in code developed for
1187 [Company].
1188 e) Code associated with open source licenses shall be carefully
1189 considered and declared to [Company] and be appraised for the potential
1190 for [Company] to declare or reveal associated intellectual property in the
1191 form of bespoke, contracted code, at any time in the future.
1192

1193 2. POST-MARKET PRODUCT MANAGEMENT

- 1194 2.1 Operating procedures are documented and approved for addressing cybersecurity
1195 patching, updating and remediation.
1196 2.2 A process is defined to facilitate ongoing product change management throughout
1197 the lifecycle of the device.
1198 2.3 A separate testing environment is established for evaluation of patches and
1199 incidents, including necessary devices and connection to backend systems.
1200 2.4 Security measures shall be reviewed including threats, breaches, user access, new
1201 vulnerability reports, assessment of risks and necessary responses, at least
1202 annually or when there is a material change in business practices.
1203 2.5 Training materials and a training plan for administration of the system including
1204 security critical roles and functions shall be established.
1205 2.6 Termination and transfer of people resources from system access, key system
1206 knowledge, and process responsibilities shall be accomplished through
1207 documented processes.
1208 2.7 Product documentation that is publicly available shall be identified and
1209 documented at least annually.
1210 2.8 A process for handling (investigating and remediating) potential vulnerabilities in
1211 products is defined.
1212 2.9 An incident mitigation and response plan is developed, including a timeframe
1213 during which mitigation occurs.

- 1214 2.10 Complaint handling systems include notification to [Company] product owner
1215 and [Company's] product security organization if a cybersecurity complaint is
1216 reported by a customer.
1217 2.11 The [Company] product owner and [Company's] product security organization
1218 shall be immediately notified if a cybersecurity issue is identified in a product.
1219 2.12 At the request of [Company] product owners and stakeholders, documentation
1220 and/or evidence of the above shall be made available.
1221

1222 **Appendix G: Example Customer Security Documentation**

1223 Customers require security documentation to enable more robust risk assessments, identify
1224 configurable security controls, and allow them to better protect their systems. This appendix
1225 section provides an overview of items that may be included in Customer Security
1226 Documentation. The following are examples of the types of information which may be included
1227 in documentation of security for medical devices or health IT:

- 1228 • Product Description
- 1229 • Hardware Specifications
- 1230 • Operating Systems
- 1231 • Third-party Software
- 1232 • Network Ports and Services
- 1233 • Sensitive Information and Data Transmitted
- 1234 • Sensitive Information and Data Stored
- 1235 • Network and Data Flow Diagram
- 1236 • Malware Protection
- 1237 • Authentication
- 1238 • Network Controls
- 1239 • Physical Controls
- 1240 • Encryption
- 1241 • Audit Logging
- 1242 • Remote Connectivity
- 1243 • Service Handling
- 1244 • End-of-Life and End-of-Support
- 1245 • Secure Coding Standards
- 1246 • System Hardening Standards
- 1247 • Risk Summary
- 1248 • Third Party Certification or Attestation
- 1249 • Manufacturer's Disclosure Statement for Medical Device Security

1250 1251 **Product Description**

1252 [Insert basic description of function or purpose of the product or solution. Photo is optional, but
1253 recommended.]

1254 1255 **Hardware Specifications**

1256 [List hardware components and specs]

1257 • [List]

1258 • [List]

1259 **Operating Systems**

1260 [List hardware operating systems and versions]

1261 • [List]

1262 • [List]

1263 **Third-party Software**

1264 [Also referred to as a Bill of Materials (BOM), includes a list of third-party software and version
1265 numbers where applicable. Having a cybersecurity bill of materials will aid customers in
1266 mitigating cybersecurity concerns on their healthcare technologies and ultimately to the
1267 systems/networks these technologies are attached to. The following are example attributes that
1268 would enable customers to leverage a bill of materials in protecting their assets.

1269 Detailed attributes include:

1270 • All commercial, open source, and custom code must be included

1271 • Commercial technology components (e.g. processors, network cards, sound cards,
1272 graphic cards, memory) must be included

1273 • The software list will be codified using an industry standard, such as Common Platform
1274 Enumeration (CPE), Software Identification tag (SWID), or Software Package Data Exchange
1275 (SPDX) that allows the software list to be searched and used to check against vulnerability feeds

1276 • The list will be available in an electronic format that allows bulk uploading into common
1277 asset inventories, vulnerability management systems and configuration management databases.

1278 • The BOM will be provided to a customer both upon a purchase and after significant
1279 software or hardware upgrades

1280 • Vendors will maintain a BOM for all product versions that will be accessible remotely by
1281 customers]

1282

Vendor and Name	Version	Description
[e.g. Microsoft Windows 10]	[e.g. 1607]	[e.g. Long Term Servicing Branch]

1283 **Network Ports and Services**

1284 [List Network Ports and Services]

Port	Protocol	Service Name	Description of Service	Encrypted	Open/Closed
XXX	XXX	XXXXX	XXXXX	XXX	XXX

1285

1286 **Sensitive Information and Data Transmitted**

1287 [List sensitive information and data transmitted. This can include PHI/PII/Potential access to
1288 wireless credentials, etc.]

1289 • [List]

1290 • [List]

1291 **Sensitive Information and Data Stored**

1292 [List sensitive information and data stored. This can include PHI/PII/Potential access to wireless
1293 credentials, etc.]

1294 • [List]

1295 • [List]

1296 **Network and Data Flow Diagram**

1297 [Provide a diagram that describes how the product resides in a customer environment, showing
1298 the system components (1 or N computers, routers, switches, adjacent systems, remote
1299 connectivity) types of connectivity (e.g. RS232, RJ45, Serial to TCP/IP conversion), what types
1300 of data is in transit and at rest (e.g. PHI, QC, config data), and how these are secured (e.g. in
1301 transit IPsec, HTTPS/TLS, WIFI WPA2PSK; at rest BitLocker, SQL TDE)

1302 **Important:** include if the device makes PHI/PII available via network or point-to-point
1303 connection (wired/wireless)?

1304 • Is connected data encrypted in transit?

1305 • Does service have network or p-to-p access to PHI (remote or in-room)?]

1306

1307 **Malware Protection**

1308 [Describe and recommend the anti-malware measures available (e.g. validated AV solutions, AV
1309 partners, how AV is managed, application whitelisting like AppLocker or McAfee Embedded
1310 Control, advanced antimalware solutions, software restriction policies)]

1311

1312 **Patch Management**

1313 [Describe and recommend the method in which we maintain, provide and deploy patch updates
1314 for this product. Examples include, “Patches are installed by a field service engineer during a
1315 routine service visit or during the yearly service visit. In the even that there is no patch
1316 management solution in place, also communicate this in this section.]

1317

1318 **Authentication & Authorization**

1319 [Describe and recommend the controls that customers have with user’s authenticating and
1320 granting permissions to features and functionality, how users are managed, the default use
1321 accounts on the system and how to change and configure accounts. This includes the ability to
1322 disable user accounts]

1323

1324 **Network Controls**

1325 [Describe and recommend the firewall rules, IPSec rules, host file restrictions, browser Internet
1326 access restrictions, MAC and IP address filtering)]

1327

1328 **Encryption**

1329 [Describe and recommend where and how encryption is applied on the system (e.g. all network
1330 traffic is TLS 1.2, at rest is BitLocker with AES 256)]

1331

1332 **Audit Logging**

1333 [Describe the audit logging process, where they are stored, what an auditable event entails, who
1334 has access to audit logs and any file permissions. Describe if audit logs are synchronized with
1335 reliable time sources and have the proper time zone set or no time offset (e.g., GMT or UTC).

1336 • What is the typical and maximum number of records retained on the device when in use?

1337 • Do users have a means to irreversibly delete audit log records in the device?

1338 • Does Service ever retain copies of PHI/PII data (is it encrypted by service) in audit logs?

1339 • Application Auditing

1340 ○ Audit file location: E:\PieRoot\Logfiles*.pld

1341 ○ Audit files hashed with SHA256 when complete for integrity.

1342 ○ Auditable Events:

1343 ■ Service Start/Stop

1344 ■ User login/logout

1345 ■ User session created/destroyed.

1346 ■ User login from multiple workstations.

1347 ■ Client application connect/disconnect with IP address and port.

1348 ■ Failed client connection attempts.

1349 ■ Changes in application configuration.

1350 ■ Failed/successful attempts to access, modify, or delete security objects;
1351 e.g. roles, permissions, etc.

1352 • Audit file permissions:

1353 ○ Administrators group: Read.

1354 ○ Auditors group: Read.

1355 ○ DB Auditors group: Full control.

1356 ○ DB Administrators group: Full control.

1357 ○ Virtual/Managed service accounts (audit file creators): Full control.

1358 ○ Users: None.]

1359 **Remote Connectivity**

1360 [Describe the nature of remote connectivity, what ports, protocols, URLs and endpoints for
1361 communication as well as security measures applied to the remote connection (e.g. TLS)]

1362

1363 **Service Handling**

1364 [Describe what routine maintenance service personnel perform, what security policies and
1365 procedures they follow (e.g. never take PHI or PII, on-site authorization protocol, encrypted
1366 Removable Media, hardened service laptops, whether or not service laptops connect to product,

1367 routine AV update during visit, secure installation/implementation principles, service
1368 authentication to product, decommissioning process, once decommissioned how the product hard
1369 drive is wiped, how the product is recovered from the field or destroyed, and what customer data
1370 and features service personnel interact with)]

1371
1372 **End-of-Life and End-of-Support**

1373 [Describe the life cycle of the product in relation to when it will no longer be sold, updated, and
1374 supported. Provide dates if available otherwise describe how EOL/EOS is communicated.]

1375
1376 **Secure Coding Standards**

1377 [Describe the secure coding standards used]

- 1378 • [List the industry secure coding standards used during software development (e.g. SEI
1379 CERT Java Secure Coding Standard)]

1380 **System Hardening Standards**

1381 [Describe the secure hardening standards used, may also create appendix to list out standards
1382 used.]

Name of Standard	Version Number	Source of Standard
[Insert name of standard]	[Insert version number]	[Insert URL]

1383
1384 **Risk Summary**

1385 [This section should contain a summary of risks found within a penetration test, remediation
1386 report, or other topics and compensating controls that correspond to additional risks outlined in
1387 the product security white paper. This may also include any findings from application scans.]

1388
1389 **Appendix H: Example Organizational Structure**

1390 The intent of this appendix section is to provide an example of roles and responsibilities within
1391 organizations to support the adoption and continuous improvement of cyber security for medical
1392 devices and health IT:

1393
1394 **Medical Device Manufacturers and Health IT Vendors**

- 1395 • **Chief Product Security/Cybersecurity Officer:** Responsibility to drive product and
1396 solution security throughout a vendor organization including identifying best practices
1397 and companywide technical standards, processes, and policies, for overall governance or
1398 guidance. In addition, this individual will advise executive management, product
1399 management, project management, R&D heads and manufacturing heads with regard to
1400 security for all products, solutions and services. Responsible for implementing pre-
1401 market product security design and post-market support including cybersecurity events
1402 and incidents for products in scope. Independent of Information Security and in
1403 cooperation with the CEO, this individual will advise appropriate processes and
1404 structures to introduce security into products, solutions and services.
- 1405 • **Product Security/Cybersecurity Engineering**

- 1406 ○ Security Architects: This person will work with R&D, service, and quality
1407 organizations to research common security vulnerabilities and their remediation;
1408 develop procedures to incorporate hardening into product development; work
1409 with individual product teams in securing their products; and proactively educate
1410 teams across the company on security best practices for products under
1411 development.
- 1412 ○ Penetration Testers: This person will perform security penetration testing, ethical
1413 hacking and red team activities in order to identify unique and common
1414 vulnerabilities in products under development. This includes performing
1415 vulnerability analysis and research, formalizing security testing procedures in the
1416 product lifecycle, performing penetration testing with remediation plans and
1417 formal reporting, and supporting red team, covert, and security activities to test
1418 organizational readiness.
- 1419 ● **Product Security/Cybersecurity Incident Response**
- 1420 ○ Incident Responder: This person will manage technical strategy, process,
1421 timelines, resources and progress for incidents relating to products at customer
1422 sites or with security researchers.
- 1423 ○ Vulnerability Manager: This person will track the escalation, follow-up, and
1424 remediation of vulnerabilities throughout the product lifecycle.
- 1425 ● **Product Security/Cybersecurity Program Management**
- 1426 ○ Policy and Compliance Analyst: This person will ensure the adoption and
1427 continuous improvement of security policies and procedures for products in
1428 compliance with industry standards and regulations.
- 1429 ○ Strategic Program Manager: This person will work cross-functionally to create
1430 programs and initiatives for establishing training, awareness, and fundamental
1431 capabilities for improving security of products.
- 1432 ● **Product Security Testing** – Responsible for assessing and testing products in
1433 development and in the market so as to understand cybersecurity risk and find issues
1434 before an external party does. Comprised of Product Security members and other
1435 participants (such as 3rd parties) as needed.

1436
1437 Larger organizations may choose to have multiple business or product-specific roles
1438 including a dedicated product security officer, manager, and/or engineers.

1439 **Healthcare Provider**

- 1441 ● Healthcare providers may create similar organizational structures to align with vendors
1442 under a Chief Clinical Information Security/Cybersecurity Officer, with distinct
1443 consideration for the healthcare provider’s specific needs relating to security during the
1444 procurement, operation, and decommissioning of medical devices and health IT products.
- 1445 ● A broad set of stakeholders should be involved including people from clinical practices,
1446 medical device support organizations and technology and security areas.

1447

1448 **Appendix I: Example Organizational Training**

1449 The intent of this appendix section is to provide training information that will help organizations
1450 mature their cybersecurity programs. A comprehensive training program for cybersecurity
1451 includes the following:

1452

- 1453 ● **Training Requirements**

1454 Requirements for training each relevant role must be established and periodically
1455 reviewed to determine if they need to be updated.

- 1456 ● **General Awareness Training**

1457 All relevant employees in the organization should understand the principles of
1458 cybersecurity, the framework of the organization’s program and the different roles and
1459 responsibilities for cybersecurity.

- 1460 ● **Training by Roles**

- 1461 ○ Training for Security Practitioners

- 1462 ▪ Engineers

- 1463 ● Architecture: Security experts who participate in architecting
1464 products or contribute to the security architecture components of
1465 products should be trained in secure architecture principles and
1466 patterns.

- 1467 ● Threat modeling and security risk analysis: Security experts who
1468 participate in threat modeling should be trained in the principles of
1469 threat modeling and the use of threat modeling tools, as well as
1470 methods of translating threats into a risk management framework.

- 1471 ● Design: Security experts who participate in product design or
1472 contribute to the security design of products should be trained in
1473 secure design principles and patterns.

- 1474 ● Testing: Security experts who perform or guide security testing of
1475 products should be trained in security testing methodologies, tools
1476 and interpretation of testing results.

- 1477 ● Forensics and Incident Response: Security experts who evaluate
1478 evidence of security incidents should have training in security
1479 forensic analysis in addition to practical experience. Those who
1480 participate in the incident response process should be trained in
1481 that process and the theory of incident response, in addition to
1482 practical experience.

- 1483 ▪ Penetration Testing: Penetration testers should have proper training in
1484 penetration testing techniques and tools as well as considerable practical
1485 experience before being qualified as a penetration tester for products.

- 1486 ▪ Security Officers/Directors/Managers/Advocates/Champions: Non-
1487 technical security practitioners should be trained in the secure
1488 development lifecycle, the company’s security framework and the
1489 company’s quality system.

- 1490 ○ Training for Related Activities – Non-dedicated Practitioners

- 1491 ▪ Software/firmware/hardware/systems engineers

- 1492 ● Secure Coding standards: Engineers involved in developing code
- 1493 should be trained in secure coding standards.
- 1494 ● Static and dynamic code analysis tools: Engineers involved in
- 1495 development and/or configuration management should be trained
- 1496 in the use and interpretation of automated code analysis tools.
- 1497 ▪ Sustaining engineering (maintenance for vulnerabilities): Engineers and
- 1498 product managers involved in maintenance of commercialized products
- 1499 should be trained in the interpretation of vulnerability notifications and the
- 1500 steps necessary to respond to vulnerabilities identified in the products.
- 1501 ▪ Risk managers: Risk managers should be trained on the incorporation and
- 1502 interpretation of security risks within the existing risk management
- 1503 framework.
- 1504 ▪ Requirements engineers: Requirements engineers should be trained to be
- 1505 able to incorporate standard security requirements into risk catalogs as
- 1506 well as novel requirements identified during threat modeling.
- 1507 ▪ Deployment engineers: Those responsible for deploying products in the
- 1508 field should be trained on adapting the products to the IT environment as
- 1509 well as configuring that environment, to match the security requirements
- 1510 specified for the products.
- 1511 ▪ Support and service engineers: Support and service engineers should be
- 1512 trained to recognize, remediate and escalate security issues reported or
- 1513 discovered in fielded systems.
- 1514 ▪ Information Security/IT/Systems Administration (infrastructure): Those
- 1515 responsible for defining and implementing the security infrastructure of
- 1516 the company's IT and physical environments should be trained in the
- 1517 access and protection requirements of secure development and
- 1518 manufacturing.
- 1519 ● **Periodic refreshers for awareness:** Employees who have participated in the overall
- 1520 awareness and more detailed training should be given periodic refresher training to
- 1521 remind them of the key elements of the previously acquired training.
- 1522 ● **Periodic updates for changes in threat landscape, technology, program:** As the threat
- 1523 landscape changes, as new technology is developed in cybersecurity and as the
- 1524 company's security program evolves, the training requirements and trainings themselves
- 1525 should be updated to stay in synchronization.
- 1526 ● **Qualification and Certification of Security Experts:**
- 1527 ○ Certification: Requirements for certification for security experts and practitioners
- 1528 should be established and upheld as minimum qualifications to participate in these
- 1529 activities. Certifications can be external and/or internal (based on completion and
- 1530 confirmation of an internal training regime).
- 1531 ○ On the job experience: Minimum requirements for actual experience practicing
- 1532 security activities should be specified for a person to be considered a security
- 1533 expert in a particular sub-role of expertise.
- 1534 ○ Mentoring and community: Participation in the community of experts within the
- 1535 company should be included as a requirement to be considered a security expert.
- 1536 This may include peer relationships as well as mentor-mentee relationships.

- 1537 ○ Levels of expertise: Different levels of expertise should be defined by the degree
1538 to which a practitioner has achieved these aspects of qualification. The levels
1539 should correspond to minimum requirements for specific security-related
1540 activities. For instance, a penetration tester may be allowed to be the lead tester
1541 for a product only in the case of a minimum amount of time practicing as a
1542 penetration tester.
- 1543 ● **Drills:** Periodic drills should be exercised, in order to ensure the ability of practitioners to
1544 apply trainings. These may take the form of tabletop incident response drills or full-
1545 blown red team/blue team exercises.

1546

1547 **Appendix J: Example Security Risk Assessment Methods**

1548 **Common Vulnerability Scoring System Rubric for Healthcare**

1549 CVSS provides a way to characterize and assess the severity of a cybersecurity vulnerability, and
1550 the IT industry has used it effectively to manage system and software vulnerabilities for many
1551 years. The purpose of this appendix section is to provide additional healthcare context for end
1552 users and vendors that leverage CVSS as a part of their vulnerability assessment.

1553 CVSS and its associated rubric and examples were developed for enterprise information
1554 technology systems and do not adequately reflect the clinical environment and potential patient
1555 safety impacts. As such, a CVSS supplemental rubric tailored to explicitly consider the clinical
1556 environment and potential impacts to patient safety is being developed in collaboration with
1557 subject matter experts across the medical device ecosystem. The intent is to use the rubric with
1558 CVSS to provide a consistent and standardized way to communicate the severity of a
1559 vulnerability between multiple parties, including the medical device manufacturer, hospitals,
1560 clinicians, patients, Department of Homeland Security (DHS), and vulnerability researchers.

1561 The draft “Rubric for Applying CVSS to Medical Devices” is found at
1562 <https://www.mitre.org/md-cvss-rubric>.

1563

1564 **Appendix K: CMMI® for Development**

1565 CMMI for development is a reference model that includes activities and best practices for
1566 developing products and services. There are 5 CMMI maturity levels from level 1 to level 5 and
1567 these maturity levels provide a means for organizations to assess and describe their performance.
1568 This appendix section provides an overview of these maturity levels which may also be found at
1569 <https://cmmiinstitute.com/learning/appraisals/levels>.

1570

1571 **Maturity Level 1: Initial**

1572 At maturity level 1, processes are usually ad hoc and chaotic. The organization usually does not
1573 provide a stable environment to support processes. Success in these organizations depends on the
1574 competence and heroics of the people in the organization and not on the use of proven processes.
1575 In spite of this chaos, maturity level 1 organizations often produce products and services that
1576 work, but they frequently exceed the budget and schedule documented in their plans. Maturity
1577 level 1 organizations are characterized by a tendency to overcommit, abandon their processes in

1578 a time of crisis, and be unable to repeat their successes.

1579

1580 **Maturity Level 2: Managed**

1581 At maturity level 2, the projects have ensured that processes are planned and executed in
1582 accordance with policy; the projects employ skilled people who have adequate resources to
1583 produce controlled outputs; involve relevant stakeholders; are monitored, controlled, and
1584 reviewed; and are evaluated for adherence to their process descriptions. The process discipline
1585 reflected by maturity level 2 helps to ensure that existing practices are retained during times of
1586 stress. When these practices are in place, projects are performed and managed according to their
1587 documented plans.

1588 Also at maturity level 2, the status of the work products are visible to management at defined
1589 points (e.g., at major milestones, at the completion of major tasks). Commitments are established
1590 among relevant stakeholders and are revised as needed. Work products are appropriately
1591 controlled. The work products and services satisfy their specified process descriptions, standards,
1592 and procedures.

1593

1594 **Maturity Level 3: Defined**

1595 At maturity level 3, processes are well characterized and understood, and are described in
1596 standards, procedures, tools, and methods. The organization's set of standard processes, which is
1597 the basis for maturity level 3, is established and improved over time. These standard processes
1598 are used to establish consistency across the organization. Projects establish their defined
1599 processes by tailoring the organization's set of standard processes according to tailoring
1600 guidelines. (See the definition of "organization's set of standard processes" in the glossary.)

1601

1602 A critical distinction between maturity levels 2 and 3 is the scope of standards, process
1603 descriptions, and procedures. At maturity level 2, the standards, process descriptions, and
1604 procedures can be quite different in each specific instance of the process (e.g., on a particular
1605 project). At maturity level 3, the standards, process descriptions, and procedures for a project are
1606 tailored from the organization's set of standard processes to suit a particular project or
1607 organizational unit and therefore are more consistent except for the differences allowed by the
1608 tailoring guidelines.

1609

1610 Another critical distinction is that at maturity level 3, processes are typically described more
1611 rigorously than at maturity level 2. A defined process clearly states the purpose, inputs, entry
1612 criteria, activities, roles, measures, verification steps, outputs, and exit criteria. At maturity level
1613 3, processes are managed more proactively using an understanding of the interrelationships of
1614 process activities and detailed measures of the process, its work products, and its services.
1615 At maturity level 3, the organization further improves its processes that are related to the
1616 maturity level 2 process areas. Generic practices associated with generic goal 3 that were not
1617 addressed at maturity level 2 are applied to achieve maturity level 3.

1618

1619 **Maturity Level 4: Quantitatively Managed**

1620 At maturity level 4, the organization and projects establish quantitative objectives for quality and
1621 process performance and use them as criteria in managing projects. Quantitative objectives are
1622 based on the needs of the customer, end users, organization, and process implementers. Quality

1623 and process performance is understood in statistical terms and is managed throughout the life of
1624 projects.

1625
1626 For selected subprocesses, specific measures of process performance are collected and
1627 statistically analyzed. When selecting subprocesses for analyses, it is critical to understand the
1628 relationships between different subprocesses and their impact on achieving the objectives for
1629 quality and process performance. Such an approach helps to ensure that subprocess monitoring
1630 using statistical and other quantitative techniques is applied to where it has the most overall
1631 value to the business. Process performance baselines and models can be used to help set quality
1632 and process performance objectives that help achieve business objectives.

1633
1634 A critical distinction between maturity levels 3 and 4 is the predictability of process
1635 performance. At maturity level 4, the performance of projects and selected subprocesses is
1636 controlled using statistical and other quantitative techniques, and predictions are based, in part,
1637 on a statistical analysis of fine-grained process data.

1638 **Maturity Level 5: Optimizing**

1639 At maturity level 5, an organization continually improves its processes based on a quantitative
1640 understanding of its business objectives and performance needs. The organization uses a
1641 quantitative approach to understand the variation inherent in the process and the causes of
1642 process outcomes.

1643
1644 Maturity level 5 focuses on continually improving process performance through incremental and
1645 innovative process and technological improvements. The organization's quality and process
1646 performance objectives are established, continually revised to reflect changing business
1647 objectives and organizational performance, and used as criteria in managing process
1648 improvement. The effects of deployed process improvements are measured using statistical and
1649 other quantitative techniques and compared to quality and process performance objectives. The
1650 project's defined processes, the organization's set of standard processes, and supporting
1651 technology are targets of measurable improvement activities.

1652
1653 A critical distinction between maturity levels 4 and 5 is the focus on managing and improving
1654 organizational performance. At maturity level 4, the organization and projects focus on
1655 understanding and controlling performance at the subprocess level and using the results to
1656 manage projects. At maturity level 5, the organization is concerned with overall organizational
1657 performance using data collected from multiple projects. Analysis of the data identifies shortfalls
1658 or gaps in performance. These gaps are used to drive organizational process improvement that
1659 generates measurable improvement in performance.

1660

1661
1662 ##